<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006918</article-id><article-id pub-id-type="pmc">PMC11860415</article-id><article-id pub-id-type="doi">10.3390/v17020163</article-id><article-id pub-id-type="publisher-id">viruses-17-00163</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3716-7010</contrib-id><name><surname>Di Marco</surname><given-names>Lorenza</given-names></name><xref rid="af1-viruses-17-00163" ref-type="aff">1</xref><xref rid="af2-viruses-17-00163" ref-type="aff">2</xref><xref rid="af3-viruses-17-00163" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Cannova</surname><given-names>Simona</given-names></name><xref rid="af4-viruses-17-00163" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Ferrigno</surname><given-names>Emanuele</given-names></name><xref rid="af4-viruses-17-00163" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Landro</surname><given-names>Giuseppe</given-names></name><xref rid="af4-viruses-17-00163" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Nonni</surname><given-names>Rosario</given-names></name><xref rid="af4-viruses-17-00163" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Mantia</surname><given-names>Claudia La</given-names></name><xref rid="af4-viruses-17-00163" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Cartabellotta</surname><given-names>Fabio</given-names></name><xref rid="af1-viruses-17-00163" ref-type="aff">1</xref><xref rid="af5-viruses-17-00163" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0287-1059</contrib-id><name><surname>Calvaruso</surname><given-names>Vincenza</given-names></name><xref rid="af1-viruses-17-00163" ref-type="aff">1</xref><xref rid="af4-viruses-17-00163" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Di Marco</surname><given-names>Vito</given-names></name><xref rid="af1-viruses-17-00163" ref-type="aff">1</xref><xref rid="af4-viruses-17-00163" ref-type="aff">4</xref><xref rid="c1-viruses-17-00163" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Stroffolini</surname><given-names>Tommaso</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00163"><label>1</label>SIcilian Network for Therapy, Epidemiology and Screening In Hepatology (SINTESI), 90127 Palermo, Italy; <email>lorenza.dimarco@unimore.it</email> (L.D.M.); <email>cartabellotta.fabio@fbfpa.it</email> (F.C.); <email>vincenza.calvaruso@unipa.it</email> (V.C.)</aff><aff id="af2-viruses-17-00163"><label>2</label>Department of Oncology and Hematology, Azienda Ospedaliero-University Hospital of Mod, 41124 Modena, Italy</aff><aff id="af3-viruses-17-00163"><label>3</label>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41100 Modena, Italy</aff><aff id="af4-viruses-17-00163"><label>4</label>Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy; <email>simicannova@hotmail.it</email> (S.C.); <email>e.ferrigno14@gmail.com</email> (E.F.); <email>peppe.landro@virgilio.it</email> (G.L.); <email>rosariononni@hotmail.it</email> (R.N.); <email>claudialamantia1990@gmail.com</email> (C.L.M.)</aff><aff id="af5-viruses-17-00163"><label>5</label>Department of Medicine, Buccheri-La Ferla Hospital, 90123 Palermo, Italy</aff><author-notes><corresp id="c1-viruses-17-00163"><label>*</label>Correspondence: <email>vito.dimarco@unipa.it</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>163</elocation-id><history><date date-type="received"><day>30</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The treatment landscape for hepatitis C virus (HCV) infection has transformed over the past few decades, evolving from the limited efficacy of interferon (IFN) monotherapy to the highly successful pan-genotypic direct-acting antivirals (DAAs) used today. Initially, alpha-interferon monotherapy, introduced in the 1990s, was the standard treatment, yet it provided low sustained virological response (SVR) rates and caused significant adverse effects, limiting its utility. The development of pegylated interferon (peg-IFN) improved the pharmacokinetic profile of IFN, allowing for less frequent dosing and modestly improved response rates. When combined with ribavirin, peg-IFN achieved higher SVR rates, especially in non-genotype 1 HCV infections, but the combination also brought additional side effects, such as anemia and depression. The advent of the first-generation DAAs, such as telaprevir and boceprevir, marked a significant milestone. Combined with peg-IFN and ribavirin, these protease inhibitors boosted response rates in patients with genotype 1 HCV. However, high rates of adverse effects and drug resistance remained challenges. Second-generation DAAs, like sofosbuvir and ledipasvir, introduced IFN-free regimens with improved safety profiles and efficacy. The most recent advances are pan-genotypic DAAs, including glecaprevir-pibrentasvir and sofosbuvir-velpatasvir, which offer high SVR rates across all genotypes, shorter treatment durations, and fewer side effects. Current pan-genotypic regimens represent a cornerstone in HCV therapy, providing an accessible and effective solution globally.</p></abstract><kwd-group><kwd>pan-genotypic</kwd><kwd>direct-acting antivirals DAAs</kwd><kwd>HCV</kwd><kwd>HCV therapy</kwd><kwd>peg-IFN</kwd><kwd>sustained virological response</kwd><kwd>SVR</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00163"><title>1. Introduction</title><p>The World Health Organization (WHO) estimates that 50 million people with chronic hepatitis C virus (HCV) infection live in the world, and 1 million new infections occur annually, with a global prevalence of approximately 1%. HCV is a leading cause of chronic liver disease, including cirrhosis and hepatocellular carcinoma (HCC) [<xref rid="B1-viruses-17-00163" ref-type="bibr">1</xref>,<xref rid="B2-viruses-17-00163" ref-type="bibr">2</xref>].</p><p>Chronic HCV infection is often asymptomatic, progressing over decades without detection. Without intervention, approximately 20&#x02013;30% of chronically infected individuals develop liver cirrhosis, and up to 5% may develop HCC [<xref rid="B3-viruses-17-00163" ref-type="bibr">3</xref>,<xref rid="B4-viruses-17-00163" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-00163" ref-type="bibr">5</xref>].</p><p>This progression highlights the need for effective antiviral therapy to prevent long-term liver damage and associated mortality. Antiviral therapy has been shown to reduce the incidence of cirrhosis, liver failure, and HCC by achieving sustained virological response (SVR), essentially curing the infection [<xref rid="B6-viruses-17-00163" ref-type="bibr">6</xref>,<xref rid="B7-viruses-17-00163" ref-type="bibr">7</xref>].</p><p>The development of antiviral therapy for HCV has been transformative. Treatment has evolved from interferon-based regimens, which were only modestly effective and associated with severe side effects, to highly effective direct-acting antivirals (DAAs) that provide high SVR rates with minimal adverse effects [<xref rid="B8-viruses-17-00163" ref-type="bibr">8</xref>]. The latest pan-genotypic DAAs, effective across all HCV genotypes, have simplified treatment protocols, making them accessible and effective worldwide [<xref rid="B9-viruses-17-00163" ref-type="bibr">9</xref>,<xref rid="B10-viruses-17-00163" ref-type="bibr">10</xref>].</p><p>This review aims to provide a comprehensive overview of the evolution of antiviral therapy for HCV, tracing the journey from early interferon-based regimens to the development of pan-genotypic DAAs. By examining each treatment stage&#x02019;s efficacy, safety, and limitations, it seeks to highlight the pivotal advances in HCV therapy and discuss the implications for global health and HCV elimination efforts.</p><p>The main purpose of the review is to describe the progressive and rapid effectiveness of drugs for all patients with hepatitis C, a disease for which, until 35 years ago, the etiological agent was unknown and had no cure. In light of these powerful innovations, DAAs should be available not only for developed countries, but also and at less onerous costs, for developing countries where the prevalence of HCV infection and liver disease is very high.</p></sec><sec id="sec2-viruses-17-00163"><title>2. The Era of Alpha-Interferon Monotherapy</title><p>In the early 1990s, alpha-interferon (IFN) monotherapy emerged as the first-line treatment for HCV infection, marking a milestone in the management of a disease that was often asymptomatic but could progress to severe liver damage over time [<xref rid="B11-viruses-17-00163" ref-type="bibr">11</xref>].</p></sec><sec id="sec3-viruses-17-00163"><title>3. Mechanism of Action of Alpha-Interferon</title><p>IFN is a cytokine produced by immune cells in response to viral infections. It functions by inducing an &#x0201c;antiviral state&#x0201d; within host cells. The antiviral effects are mediated through several pathways: alpha-interferon binds to receptors on the surface of target cells, activating intracellular signaling pathways, such as the JAK-STAT pathway, which leads to the transcription of interferon-stimulated genes (ISGs). These genes produce antiviral proteins that inhibit viral replication at various stages, including entry, RNA transcription, protein synthesis, and release. Interferon also enhances the immune response by promoting the activity of natural killer (NK) cells and cytotoxic T lymphocytes, which play critical roles in clearing infected cells [<xref rid="B12-viruses-17-00163" ref-type="bibr">12</xref>].</p></sec><sec id="sec4-viruses-17-00163"><title>4. Clinical Efficacy and Challenges</title><p>While alpha-interferon represented a significant advancement, the therapy was limited by low response rates and high rates of relapse post-treatment. Early studies showed that ALT levels were normalized in 35&#x02013;40% of patients, and biopsy also demonstrated histological improvement in lobular and periportal inflammation. Unfortunately, relapse was a common problem in these studies, occurring in 49&#x02013;57% of patients [<xref rid="B13-viruses-17-00163" ref-type="bibr">13</xref>,<xref rid="B14-viruses-17-00163" ref-type="bibr">14</xref>,<xref rid="B15-viruses-17-00163" ref-type="bibr">15</xref>].</p><p>The poor response rates were compounded by the significant side effects associated with interferon therapy. Common adverse effects included flu-like symptoms (fever, fatigue, myalgia), neuropsychiatric symptoms (depression, irritability), and hematologic changes, such as leukopenia and thrombocytopenia, which often required dose adjustments or even discontinuation of therapy [<xref rid="B16-viruses-17-00163" ref-type="bibr">16</xref>].</p></sec><sec id="sec5-viruses-17-00163"><title>5. Understanding the Limitations</title><p>Research during this era highlighted the inherent limitations of alpha-interferon in treating HCV. Unlike other viruses that rely on intracellular replication machinery (such as the hepatitis B virus), HCV has a high mutation rate, resulting in quasi-species or closely related viral variants that can evade immune responses. This genetic variability made HCV particularly resistant to interferon monotherapy, which could not completely suppress viral replication [<xref rid="B17-viruses-17-00163" ref-type="bibr">17</xref>,<xref rid="B18-viruses-17-00163" ref-type="bibr">18</xref>,<xref rid="B19-viruses-17-00163" ref-type="bibr">19</xref>].</p><p>Additionally, the need for frequent subcutaneous administration, often three times weekly, the limited efficacy, and the high side effect rates of alpha-interferon monotherapy underscored the need for other treatments that could enhance effectiveness and safety.</p></sec><sec id="sec6-viruses-17-00163"><title>6. Pegylated Interferon Monotherapy</title><p>The introduction of pegylated interferon (peg-IFN) in the early 2000s represented a pivotal advancement in HCV treatment. Chemically modifying IFN with polyethylene glycol (PEG) offered a more stable pharmacokinetic profile, allowing for once-weekly dosing while enhancing efficacy in suppressing HCV replication [<xref rid="B20-viruses-17-00163" ref-type="bibr">20</xref>].</p></sec><sec id="sec7-viruses-17-00163"><title>7. Mechanism and Pharmacokinetics of Pegylation</title><p>Pegylation is a process that involves attaching PEG, a large, inert molecule, to the interferon protein. This modification shields the interferon from rapid degradation and clearance, particularly by the kidneys, and reduces its immunogenicity, thereby prolonging its half-life. The PEG molecule increases the interferon&#x02019;s size, slowing its absorption and creating a controlled release mechanism that maintains stable blood levels over the week. The two primary peg-IFN formulations differ slightly in their PEG structure: peg-IFN alfa-2a uses a larger, branched PEG molecule, which provides more consistent plasma concentrations, while peg-IFN alfa-2b uses a smaller, linear PEG molecule, which is absorbed more rapidly but still offers a significant half-life extension compared to standard IFN [<xref rid="B21-viruses-17-00163" ref-type="bibr">21</xref>]. This prolonged and stable pharmacokinetic profile was beneficial for HCV treatment, as it maintained adequate drug levels without the peaks and troughs associated with standard IFN. This not only provided continuous antiviral action but also minimized the frequency of side effects that tended to arise during the peaks in standard IFN dosing [<xref rid="B22-viruses-17-00163" ref-type="bibr">22</xref>].</p></sec><sec id="sec8-viruses-17-00163"><title>8. Challenges and Limitations of Peg-IFN Monotherapy</title><p>While peg-IFN significantly improved over standard IFN, its efficacy as a monotherapy was limited. SVR rates with peg-IFN monotherapy remained suboptimal, particularly in genotype 1 patients, with approximately 60&#x02013;70% of genotype 1 patients experiencing viral relapse after treatment [<xref rid="B23-viruses-17-00163" ref-type="bibr">23</xref>,<xref rid="B24-viruses-17-00163" ref-type="bibr">24</xref>].</p></sec><sec id="sec9-viruses-17-00163"><title>9. Clinical Implications of Peg-IFN Monotherapy</title><p>Despite its limitations, peg-IFN monotherapy marked a significant step forward in HCV treatment and set the stage for combination therapy with ribavirin. The enhanced pharmacokinetics and improved SVR rates of peg-IFN compared to standard IFN provided the foundation for subsequent treatment advancements. Peg-IFN also highlighted the need for genotype-specific approaches, as genotypes 1 and 4 proved more challenging to treat with peg-IFN monotherapy [<xref rid="B25-viruses-17-00163" ref-type="bibr">25</xref>,<xref rid="B26-viruses-17-00163" ref-type="bibr">26</xref>], while genotypes 2 and 3 were more responsive [<xref rid="B27-viruses-17-00163" ref-type="bibr">27</xref>]. These findings underscored the genetic diversity of HCV and informed subsequent treatment guidelines and strategies [<xref rid="B28-viruses-17-00163" ref-type="bibr">28</xref>,<xref rid="B29-viruses-17-00163" ref-type="bibr">29</xref>].</p></sec><sec id="sec10-viruses-17-00163"><title>10. Combination Therapy with Pegylated Interferon and Ribavirin</title><p>The combination of peg-IFN with ribavirin marked a significant milestone in HCV treatment, substantially improving SVR rates compared to peg-IFN alone. Introduced in the early 2000s, this combination became the standard of care and remained the cornerstone of HCV therapy for over a decade until the advent of DAAs. Ribavirin, a nucleoside analog with broad-spectrum antiviral activity, enhanced the effectiveness of peg-IFN, particularly in achieving SVR across various HCV genotypes, though challenges persisted, especially for genotypes 1 and 4 [<xref rid="B30-viruses-17-00163" ref-type="bibr">30</xref>].</p></sec><sec id="sec11-viruses-17-00163"><title>11. Mechanism of Action of Ribavirin and Its Role in Improving SVR</title><p>Ribavirin&#x02019;s mechanism of action is complex. It is thought to exert its antiviral effects through multiple pathways, including (1) the direct inhibition of HCV replication, (2) inhibition of host inosine monophosphate dehydrogenase (IMPDH) enzyme, (3) mutagenesis induction to drive a rapidly replicating virus beyond the threshold to error catastrophe, and (4) immunomodulation by inducing a Th1 immune response. Specifically, ribavirin monophosphate (RMP) is converted to ribavirin triphosphate (RTP) forms, and binding of RTP to the nucleotide binding site of RNA polymerase prevents binding of the correct nucleotides, leading to reduced viral replication or the production of defective virions. Additionally, ribavirin monophosphate is a competitive inhibitor of IMPDH, an enzyme involved in the de novo synthesis of guanine nucleotides. This could lead to a decline in viral protein synthesis and limit the replication of viral genomes. Finally, ribavirin enhances the immune response against HCV by modulating the balance of T-helper (Th1/Th2) cells, favoring a Th1-dominant, cell-mediated immune response, which is more effective in clearing the virus [<xref rid="B31-viruses-17-00163" ref-type="bibr">31</xref>].</p><p>In combination with peg-IFN, ribavirin enhances the SVR by increasing the likelihood of viral eradication, particularly when administered over an extended period [<xref rid="B32-viruses-17-00163" ref-type="bibr">32</xref>].</p></sec><sec id="sec12-viruses-17-00163"><title>12. SVR Rates Across Different HCV Genotypes</title><p>HCV genotype plays a crucial role in determining treatment response. Peg-IFN alfa-2b plus ribavirin achieved significantly higher SVR rates compared to interferon alfa-2b plus ribavirin across all HCV genotypes (<xref rid="viruses-17-00163-t001" ref-type="table">Table 1</xref>). However, response rates varied by genotype. For patients with genotype 1, the most prevalent and hardest-to-treat genotype, the SVR rate was around 42% with combination therapy, compared to lower rates with interferon alone. This represented a meaningful improvement but left a substantial proportion of genotype 1 patients without an effective cure.</p><p>In contrast, patients with genotypes 2 and 3 responded much more favorably to the combination therapy, with SVR rates of around 76&#x02013;82%. This high efficacy in genotypes 2 and 3 led to shorter treatment durations (24 weeks instead of 48 weeks), given that these genotypes were more susceptible to the antiviral effects of the combined therapy. Genotype 4, more prevalent in regions such as the Middle East and North Africa, exhibited intermediate SVR rates of approximately 55&#x02013;60%, presenting additional challenges in achieving complete viral eradication compared to genotypes 2 and 3 [<xref rid="B33-viruses-17-00163" ref-type="bibr">33</xref>,<xref rid="B34-viruses-17-00163" ref-type="bibr">34</xref>,<xref rid="B35-viruses-17-00163" ref-type="bibr">35</xref>,<xref rid="B36-viruses-17-00163" ref-type="bibr">36</xref>,<xref rid="B37-viruses-17-00163" ref-type="bibr">37</xref>,<xref rid="B38-viruses-17-00163" ref-type="bibr">38</xref>,<xref rid="B39-viruses-17-00163" ref-type="bibr">39</xref>,<xref rid="B40-viruses-17-00163" ref-type="bibr">40</xref>,<xref rid="B41-viruses-17-00163" ref-type="bibr">41</xref>].</p></sec><sec id="sec13-viruses-17-00163"><title>13. Adverse Effects of Ribavirin, Especially Hematological Toxicity</title><p>While ribavirin enhanced treatment efficacy, it also introduced significant adverse effects, particularly hematological toxicity. The most notable side effect is hemolytic anemia, which occurs because ribavirin accumulates in red blood cells, causing oxidative damage that leads to hemolysis [<xref rid="B42-viruses-17-00163" ref-type="bibr">42</xref>]. Ribavirin can also exacerbate the neuropsychiatric side effects associated with interferon, such as depression and irritability, impacting patient adherence [<xref rid="B43-viruses-17-00163" ref-type="bibr">43</xref>,<xref rid="B44-viruses-17-00163" ref-type="bibr">44</xref>].</p></sec><sec id="sec14-viruses-17-00163"><title>14. The Introduction of Direct-Acting Antivirals (DAAs): First Generation</title><p>The introduction of DAAs marked a turning point in HCV treatment, revolutionizing approaches with enhanced efficacy compared to prior therapies. The first-generation DAAs, notably protease inhibitors such as boceprevir and telaprevir, were designed to target viral replication, significantly advancing the treatment landscape for chronic HCV patients.</p></sec><sec id="sec15-viruses-17-00163"><title>15. Mechanism of Action: NS3/4A Protease Inhibition</title><p>Boceprevir and telaprevir became FDA-approved in 2011 as the first DAAs targeting the HCV NS3/4A protease, a crucial enzyme in viral replication [<xref rid="B45-viruses-17-00163" ref-type="bibr">45</xref>,<xref rid="B46-viruses-17-00163" ref-type="bibr">46</xref>]. By binding to the active site of this protease, boceprevir and telaprevir effectively turn off the protease&#x02019;s function, halting the replication process. Unlike previous interferon-based therapies, these protease inhibitors offered a mechanism of action specific to the virus, opening the door to targeted antiviral therapy and transforming the treatment paradigm by focusing on viral pathways rather than general immune system modulation [<xref rid="B47-viruses-17-00163" ref-type="bibr">47</xref>,<xref rid="B48-viruses-17-00163" ref-type="bibr">48</xref>,<xref rid="B49-viruses-17-00163" ref-type="bibr">49</xref>].</p></sec><sec id="sec16-viruses-17-00163"><title>16. Improvements in Sustained Virological Response (SVR) Rates</title><p>One of the key benefits of first-generation DAAs was their impact on SVR rates, a crucial indicator of HCV treatment efficacy. Clinical trials demonstrated that adding boceprevir or telaprevir to the existing standard of care&#x02014;typically PEG-IFN and ribavirin&#x02014;dramatically improved SVR rates, especially in patients with genotype 1 HCV, the most challenging to treat with IFN-based therapies alone (<xref rid="viruses-17-00163-t002" ref-type="table">Table 2</xref>). For example, telaprevir-based regimens achieved SVR rates between 67% and 79% in treatment-na&#x000ef;ve genotype 1 patients, a substantial improvement over the approximate 40% SVR rates seen with PEG-IFN and ribavirin alone [<xref rid="B50-viruses-17-00163" ref-type="bibr">50</xref>,<xref rid="B51-viruses-17-00163" ref-type="bibr">51</xref>,<xref rid="B52-viruses-17-00163" ref-type="bibr">52</xref>,<xref rid="B53-viruses-17-00163" ref-type="bibr">53</xref>,<xref rid="B54-viruses-17-00163" ref-type="bibr">54</xref>,<xref rid="B55-viruses-17-00163" ref-type="bibr">55</xref>,<xref rid="B56-viruses-17-00163" ref-type="bibr">56</xref>,<xref rid="B57-viruses-17-00163" ref-type="bibr">57</xref>].</p></sec><sec id="sec17-viruses-17-00163"><title>17. Challenges and Limitations: Resistance, Complex Dosing, and Drug&#x02013;Drug Interactions</title><p>Despite their efficacy, first-generation DAAs presented significant challenges, including the risk of viral resistance, adverse effects, and complex treatment regimens. Resistance was a notable issue; since these DAAs targeted a single viral enzyme, mutations in the NS3/4A protease could render the drugs less effective. Resistance-associated variants (RAVs) often emerged during treatment, particularly in patients who experienced incomplete viral suppression. This challenge emphasized the need for combination therapies targeting multiple viral components to reduce the risk of resistance [<xref rid="B58-viruses-17-00163" ref-type="bibr">58</xref>].</p><p>Another major limitation of first-generation DAAs was their reliance on interferon. Boceprevir and telaprevir were not administered as standalone therapies; rather, they were combined with PEG-IFN and ribavirin, which brought additional adverse effects and lengthy treatment durations. IFN-based regimens were associated with side effects such as fatigue, flu-like symptoms, and hematologic abnormalities, often making adherence challenging for patients. Moreover, the DAAs themselves introduced side effects, including anemia, rash, and gastrointestinal disturbances, further complicating treatment [<xref rid="B59-viruses-17-00163" ref-type="bibr">59</xref>,<xref rid="B60-viruses-17-00163" ref-type="bibr">60</xref>,<xref rid="B61-viruses-17-00163" ref-type="bibr">61</xref>].</p><p>Finally, first-generation DAAs also required intricate dosing schedules, demanding strict patient adherence. The potential for drug&#x02013;drug interactions exacerbated this complexity, as boceprevir and telaprevir were metabolized by the liver enzyme CYP3A. This led to interactions with many other medications, particularly those affecting hepatic function. The narrow therapeutic window of these drugs made managing comorbid conditions challenging and sometimes necessitated additional monitoring or dose adjustments for concomitant medications [<xref rid="B62-viruses-17-00163" ref-type="bibr">62</xref>,<xref rid="B63-viruses-17-00163" ref-type="bibr">63</xref>,<xref rid="B64-viruses-17-00163" ref-type="bibr">64</xref>,<xref rid="B65-viruses-17-00163" ref-type="bibr">65</xref>].</p><list list-type="simple"><list-item><p>
<bold>Biological insights that led to development of DAAs</bold>
</p></list-item></list><p>The development of DAAs was driven by several pivotal biological insights into the virus&#x02019;s life cycle and molecular biology. These insights enabled the identification of highly specific therapeutic targets within the virus (<xref rid="viruses-17-00163-t003" ref-type="table">Table 3</xref>).</p><list list-type="order"><list-item><p>Understanding the HCV Genome and Polyprotein Processing</p></list-item></list><p>The HCV genome is a positive-sense single-stranded RNA (~9.6 kb) that encodes a single polyprotein. This polyprotein is cleaved into structural proteins (core, E1, E2) and non-structural (NS) proteins (NS3, NS4A, NS4B, NS5A, and NS5B) by host and viral proteases. The viral NS proteins were identified as critical components for replication and virion assembly, making them ideal targets for DAAs.</p><list list-type="simple"><list-item><label>2.</label><p>Role of NS3/4A Protease in Viral Maturation.</p></list-item></list><p>NS3/4A is a serine protease that cleaves the HCV polyprotein at specific junctions, producing functional proteins required for viral replication. Inhibiting NS3/4A blocks the processing of the polyprotein, halting replication at an early stage. Protease inhibitors (e.g., Glecaprevir, Voxilaprevir) were designed to bind the NS3/4A active site, preventing substrate processing.</p><list list-type="simple"><list-item><label>3.</label><p>RNA-Dependent RNA Polymerase as the Engine of Replication</p></list-item></list><p>NS5B is an RNA-dependent RNA polymerase responsible for synthesizing the viral RNA genome. It is highly conserved across HCV genotypes. NS5B became a key target for therapeutic intervention, as inhibiting it would directly halt genome replication. Nucleoside inhibitors (e.g., Sofosbuvir) mimic natural nucleotides and are incorporated into the viral RNA, causing chain termination. Non-nucleoside inhibitors (e.g., Dasabuvir) bind allosterically to NS5B, reducing its enzymatic activity.</p><list list-type="simple"><list-item><label>4.</label><p>Multifunctional Role of NS5A in Viral Replication and Assembly</p></list-item></list><p>NS5A is a phosphoprotein involved in multiple steps of the HCV life cycle, including replication, assembly, and interactions with host factors. NS5A inhibitors disrupt the replication complex and virion assembly, resulting in a reduction in infectious virus production. Drugs like Ledipasvir, Velpatasvir, and Pibrentasvir were designed to bind NS5A, leveraging its role as a central hub in viral replication.</p><list list-type="simple"><list-item><label>5.</label><p>Role of Host&#x02013;Virus Interactions</p></list-item></list><p>HCV relies on host factors, such as lipid metabolism pathways and cellular chaperones, to facilitate its replication and assembly. Early therapies targeted host factors (e.g., interferons), but the high specificity of DAAs for viral proteins minimized off-target effects and adverse reactions. The focus on direct viral targets reduced dependency on host-directed strategies, improving efficacy and tolerability.</p><list list-type="simple"><list-item><label>6.</label><p>Genotype-Specific Variations.</p></list-item></list><p>HCV exhibits genetic diversity with seven major genotypes and numerous subtypes, which affect drug sensitivity and resistance patterns. Understanding genotype-specific differences informed the design of pan-genotypic DAAs, such as Sofosbuvir and Velpatasvir, which target conserved regions of the virus.</p><list list-type="simple"><list-item><label>7.</label><p>Viral Resistance Mechanisms.</p></list-item></list><p>HCV&#x02019;s high replication rate and lack of proofreading by NS5B polymerase lead to the rapid generation of quasispecies, promoting resistance. Combination therapy targeting multiple viral proteins simultaneously was developed to prevent resistance and enhance treatment efficacy.</p><list list-type="simple"><list-item><label>8.</label><p>Advances in Structural Biology and Drug Design</p></list-item></list><p>High-resolution crystal structures of HCV proteins (e.g., NS3/4A, NS5A, and NS5B) provided a detailed understanding of their active sites and interaction dynamics. Structure-based drug design enabled the development of DAAs with high specificity and potency [<xref rid="B66-viruses-17-00163" ref-type="bibr">66</xref>,<xref rid="B67-viruses-17-00163" ref-type="bibr">67</xref>,<xref rid="B68-viruses-17-00163" ref-type="bibr">68</xref>,<xref rid="B69-viruses-17-00163" ref-type="bibr">69</xref>,<xref rid="B70-viruses-17-00163" ref-type="bibr">70</xref>,<xref rid="B71-viruses-17-00163" ref-type="bibr">71</xref>,<xref rid="B72-viruses-17-00163" ref-type="bibr">72</xref>,<xref rid="B73-viruses-17-00163" ref-type="bibr">73</xref>,<xref rid="B74-viruses-17-00163" ref-type="bibr">74</xref>,<xref rid="B75-viruses-17-00163" ref-type="bibr">75</xref>,<xref rid="B76-viruses-17-00163" ref-type="bibr">76</xref>,<xref rid="B77-viruses-17-00163" ref-type="bibr">77</xref>].</p><p>These insights into the molecular and structural biology of HCV, combined with advances in medicinal chemistry, allowed the development of DAAs that transformed HCV therapy. The ability to target multiple stages of the virus life cycle, combined with the advent of pan-genotypic agents, has resulted in cure rates exceeding 95% for most patients.</p></sec><sec id="sec18-viruses-17-00163"><title>18. Efficacy and Improved Tolerability in IFN-Free Regimens</title><p>Clinical trials revealed that sofosbuvir, combined with ribavirin or other DAAs, achieved high SVR rates across multiple HCV genotypes. For instance, in genotype 1 patients&#x02014;a group previously challenging to treat&#x02014;sofosbuvir-based regimens demonstrated SVR rates exceeding 90% when combined with other DAAs such as ledipasvir [<xref rid="B78-viruses-17-00163" ref-type="bibr">78</xref>]. Genotype 2 and 3 patients also showed excellent responses, with SVR rates around 93&#x02013;97% when sofosbuvir was combined with ribavirin alone, eliminating the need for IFN [<xref rid="B79-viruses-17-00163" ref-type="bibr">79</xref>]. This shift allowed for shorter, simpler treatment courses with fewer side effects, increasing patient adherence and satisfaction.</p></sec><sec id="sec19-viruses-17-00163"><title>19. Impact on Treatment Adherence and Sustained Virological Response (SVR)</title><p>The shift from IFN-based to IFN-free regimens profoundly affected treatment adherence and SVR rates. IFN has been associated with a range of side effects, including flu-like symptoms, depression, and hematologic abnormalities, often leading to early treatment discontinuation. Sofosbuvir-based IFN-free regimens addressed this issue by providing a more tolerable therapy with fewer adverse events, enabling patients to complete their treatment courses. The high efficacy and low side effect profile of sofosbuvir made it feasible to offer treatment to a wider range of patients, including those previously ineligible for IFN-based regimens, such as those with advanced liver disease or liver transplantation [<xref rid="B80-viruses-17-00163" ref-type="bibr">80</xref>,<xref rid="B81-viruses-17-00163" ref-type="bibr">81</xref>,<xref rid="B82-viruses-17-00163" ref-type="bibr">82</xref>,<xref rid="B83-viruses-17-00163" ref-type="bibr">83</xref>,<xref rid="B84-viruses-17-00163" ref-type="bibr">84</xref>].</p></sec><sec id="sec20-viruses-17-00163"><title>20. Efficacy, Tolerability, and Reduced Treatment Duration of Combination Therapies</title><p>The combination therapies in second- and third-generation DAAs offer superior efficacy, with SVR rates often surpassing 95% and, in some cases, approaching 100%, particularly in treatment-na&#x000ef;ve patients (<xref rid="viruses-17-00163-t004" ref-type="table">Table 4</xref>). The ledipasvir&#x02013;sofosbuvir combination, for example, showed exceptional efficacy for HCV genotype 1 patients, achieving SVR rates of 94&#x02013;100% depending on prior treatment history and the presence of cirrhosis. This combination also demonstrated remarkable tolerability, with mild side effects such as headache and fatigue being the most reported, significantly improving the severe adverse effects of interferon-based therapies [<xref rid="B85-viruses-17-00163" ref-type="bibr">85</xref>,<xref rid="B86-viruses-17-00163" ref-type="bibr">86</xref>,<xref rid="B87-viruses-17-00163" ref-type="bibr">87</xref>,<xref rid="B88-viruses-17-00163" ref-type="bibr">88</xref>].</p><p>Another potent combination, daclatasvir&#x02013;asunaprevir, has also proven effective across genotypes. Studies show that these combinations maintain high efficacy and tolerability, particularly for genotypes 1 and 3, which were historically challenging to treat. These regimens improve patient comfort and quality of life and enhance adherence, as patients are less likely to discontinue due to adverse effects [<xref rid="B89-viruses-17-00163" ref-type="bibr">89</xref>,<xref rid="B90-viruses-17-00163" ref-type="bibr">90</xref>].</p><p>One of the most transformative aspects of modern DAA therapies is the reduced treatment duration. Earlier regimens required 24&#x02013;48 weeks of treatment, whereas modern DAA combinations can achieve high SVR rates in as little as 8&#x02013;12 weeks for most patients. This shorter duration is especially beneficial for patients with complex medical profiles or limited ability to adhere to long treatment courses.</p><p>Finally, DAA therapies are also highly effective in populations previously considered difficult to treat, including patients with cirrhosis or liver transplant, those co-infected with HIV, and individuals who have relapsed after prior treatment attempts [<xref rid="B91-viruses-17-00163" ref-type="bibr">91</xref>,<xref rid="B92-viruses-17-00163" ref-type="bibr">92</xref>].</p></sec><sec id="sec21-viruses-17-00163"><title>21. Pan-Genotypic DAAs: The Latest Generation</title><p>The development of pan-genotypic DAAs marks a significant advance in HCV therapy by introducing regimens effective across all major HCV genotypes. Unlike earlier treatments that required genotype-specific regimens, pan-genotypic DAAs, such as glecaprevir-pibrentasvir [<xref rid="B93-viruses-17-00163" ref-type="bibr">93</xref>,<xref rid="B94-viruses-17-00163" ref-type="bibr">94</xref>] and sofosbuvir-velpatasvir [<xref rid="B95-viruses-17-00163" ref-type="bibr">95</xref>,<xref rid="B96-viruses-17-00163" ref-type="bibr">96</xref>,<xref rid="B97-viruses-17-00163" ref-type="bibr">97</xref>], are designed to target multiple genotypes, simplifying the treatment landscape. This shift reduces the need for genotype testing before initiating therapy, enabling faster, more accessible treatment on a global scale. These drugs not only achieve high SVR rates across genotypes but also offer improved tolerability and shorter treatment durations (8 or 12 weeks), even for hard-to-treat patient populations [<xref rid="B98-viruses-17-00163" ref-type="bibr">98</xref>].</p></sec><sec id="sec22-viruses-17-00163"><title>22. High SVR Rates, Improved Tolerability, and Simplified Treatment Regimens</title><p>Pan-genotypic DAAs deliver high SVR rates across HCV genotypes, even among patient populations traditionally considered challenging to treat (<xref rid="viruses-17-00163-t005" ref-type="table">Table 5</xref>). Clinical trials have shown that the sofosbuvir&#x02013;velpatasvir combination [<xref rid="B99-viruses-17-00163" ref-type="bibr">99</xref>,<xref rid="B100-viruses-17-00163" ref-type="bibr">100</xref>,<xref rid="B101-viruses-17-00163" ref-type="bibr">101</xref>] and glecaprevir&#x02013;pibrentasvir combination [<xref rid="B102-viruses-17-00163" ref-type="bibr">102</xref>,<xref rid="B103-viruses-17-00163" ref-type="bibr">103</xref>] achieve SVR rates exceeding 95% in patients across all major genotypes, including those with cirrhosis and previous treatment failure. The combination therapy of Sofosbuvir, Velpatasvir, and Voxilaprevir represents a powerful option, particularly for patients who have previously failed treatment with other antiviral regimens [<xref rid="B104-viruses-17-00163" ref-type="bibr">104</xref>].</p><p>These pan-genotypic regimens are associated with minimal side effects, typically limited to mild symptoms such as headache, fatigue, and nausea. This improved tolerability represents a major shift from the adverse effect profiles of older treatments, particularly interferon-based regimens, which often caused significant side effects leading to treatment discontinuation. The reduced adverse event profile of pan-genotypic DAAs contributes to better patient adherence and overall treatment success, as patients are less likely to experience side effects that could otherwise hinder their ability to complete the regimen [<xref rid="B105-viruses-17-00163" ref-type="bibr">105</xref>,<xref rid="B106-viruses-17-00163" ref-type="bibr">106</xref>,<xref rid="B107-viruses-17-00163" ref-type="bibr">107</xref>,<xref rid="B108-viruses-17-00163" ref-type="bibr">108</xref>,<xref rid="B109-viruses-17-00163" ref-type="bibr">109</xref>,<xref rid="B110-viruses-17-00163" ref-type="bibr">110</xref>].</p></sec><sec id="sec23-viruses-17-00163"><title>23. Current Recommendations and Future Perspectives</title><p>Current guidelines for hepatitis C virus (HCV) treatment from major liver societies, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) emphasize the use of pan-genotypic DAAs for simplified, highly effective treatment across all HCV genotypes [<xref rid="B9-viruses-17-00163" ref-type="bibr">9</xref>,<xref rid="B10-viruses-17-00163" ref-type="bibr">10</xref>]. These guidelines recommend DAAs like glecaprevir-pibrentasvir and sofosbuvir-velpatasvir as first-line treatments due to their high SVR rates, minimal side effects, and shorter treatment durations, which often range from 8 to 12 weeks for most patient populations. The guidelines also suggest routine HCV screening for all adults and prioritize treatment for high-risk groups, including those with advanced liver disease and individuals co-infected with HIV.</p></sec><sec id="sec24-viruses-17-00163"><title>24. Remaining Challenges and Future Directions</title><p>Despite advances in HCV therapy, challenges persist. Reinfection, especially among populations with higher-risk behaviors (such as injection drug users), poses a significant obstacle to long-term viral elimination. Addressing this requires effective antiviral treatments and public health measures, such as harm reduction programs and access to preventive care [<xref rid="B111-viruses-17-00163" ref-type="bibr">111</xref>,<xref rid="B112-viruses-17-00163" ref-type="bibr">112</xref>,<xref rid="B113-viruses-17-00163" ref-type="bibr">113</xref>,<xref rid="B114-viruses-17-00163" ref-type="bibr">114</xref>]. Additionally, limited accessibility to DAAs in low-resource settings hampers global efforts to eradicate HCV. High treatment costs and inadequate healthcare infrastructure in some regions continue to restrict access, making it challenging to achieve universal HCV elimination [<xref rid="B115-viruses-17-00163" ref-type="bibr">115</xref>].</p><p>Looking ahead, the focus is on making HCV treatment even more accessible and effective. Pan-genotypic regimens and simplified dosing protocols reduce the need for extensive pre-treatment testing and make therapy more accessible in diverse clinical settings.</p><p>As part of a global elimination effort, there is growing emphasis on community-based screening, decentralizing treatment, and developing point-of-care diagnostics to identify and treat HCV infections more rapidly [<xref rid="B116-viruses-17-00163" ref-type="bibr">116</xref>].</p><p>Finally, a major unsolved problem remains the high cost of drugs. Reducing drug costs requires a comprehensive approach that addresses economic, regulatory and market factors [<xref rid="B117-viruses-17-00163" ref-type="bibr">117</xref>].</p><p>Policy options could include the following:<list list-type="order"><list-item><p>The production of generic drugs by encouraging early patent expiration or negotiating compulsory licenses to allow the production of low-cost generic versions.</p></list-item><list-item><p>Centralized purchasing by governments or health organizations that can adopt large-scale supply models, negotiating directly with manufacturers to secure lower prices.</p></list-item><list-item><p>Market competition to promote the entry of more manufacturers by offering tax incentives or reducing regulatory barriers, increasing competition and lowering prices.</p></list-item><list-item><p>Public&#x02013;private partnerships to collaborate with pharmaceutical companies to develop and produce drugs, ensuring affordable prices in exchange for research support.</p></list-item><list-item><p>Public funding to invest in the research and development of treatments that are not subject to the profit-driven models of private companies.</p></list-item><list-item><p>Price controls to set maximum price caps for essential medicines or impose regulations on pharmaceutical companies&#x02019; profit margins.</p></list-item><list-item><p>Tax exemptions and incentives to reduce taxes or duties on raw materials and finished medicines to lower production and distribution costs.</p></list-item></list></p><p>These options must be adapted to local regulatory, economic and health contexts, while balancing affordability, innovation and sustainability for health systems.</p><p>Through these strategies, and with continued support from international health organizations, there is optimism that HCV can be eliminated as a public health threat within the coming decades.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, L.D.M., V.C. and V.D.M.; methodology, L.D.M. and F.C.; resources L.D.M. and C.L.M.; data curation, L.D.M., S.C., E.F., G.L., R.N. and C.L.M.; writing&#x02014;original draft preparation, L.D.M.; writing&#x02014;review and editing, F.C., V.C. and V.D.M.; supervision, V.D.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Vincenza Calvaruso served on the advisory board of Abbvie, Gilead, Ipsen, and Advanz. Vito Di Marco received research support from Abbvie and Gilead, and served on the advisory boards of Abbvie, Gilead, and Ipsen. Fabio Cartabellotta received research support from Abbvie and Gilead. The other authors have no disclosures to declare.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-00163"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>Global Hepatitis Report 2017</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2017</year></element-citation></ref><ref id="B2-viruses-17-00163"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>Polaris Observatory HCV Collaborators</collab>
</person-group><article-title>Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study</article-title><source>Lancet Gastroenterol. Hepatol.</source><year>2022</year><volume>7</volume><fpage>396</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(21)00472-6</pub-id><pub-id pub-id-type="pmid">35180382</pub-id>
</element-citation></ref><ref id="B3-viruses-17-00163"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alter</surname><given-names>M.J.</given-names></name>
<name><surname>Margolis</surname><given-names>H.S.</given-names></name>
<name><surname>Krawczynski</surname><given-names>K.</given-names></name>
<name><surname>Judson</surname><given-names>F.N.</given-names></name>
<name><surname>Mares</surname><given-names>A.</given-names></name>
<name><surname>Alexander</surname><given-names>W.</given-names></name>
<name><surname>Hu</surname><given-names>P.Y.</given-names></name>
<name><surname>Miller</surname><given-names>J.K.</given-names></name>
<name><surname>Gerber</surname><given-names>M.A.</given-names></name>
<name><surname>Sampliner</surname><given-names>R.E.</given-names></name>
<etal/>
</person-group><article-title>The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team</article-title><source>N. Engl. J. Med.</source><year>1992</year><volume>327</volume><fpage>1899</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.1056/NEJM199212313272702</pub-id><pub-id pub-id-type="pmid">1280771</pub-id>
</element-citation></ref><ref id="B4-viruses-17-00163"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davis</surname><given-names>G.L.</given-names></name>
<name><surname>Alter</surname><given-names>M.J.</given-names></name>
<name><surname>El-Serag</surname><given-names>H.</given-names></name>
<name><surname>Poynard</surname><given-names>T.</given-names></name>
<name><surname>Jennings</surname><given-names>L.W.</given-names></name>
</person-group><article-title>Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>513</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.09.067</pub-id><pub-id pub-id-type="pmid">19861128</pub-id>
</element-citation></ref><ref id="B5-viruses-17-00163"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alter</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Epidemiology of hepatitis C virus infection</article-title><source>World J. Gastroenterol.</source><year>2007</year><volume>13</volume><fpage>2436</fpage><lpage>2441</lpage><pub-id pub-id-type="doi">10.3748/wjg.v13.i17.2436</pub-id><pub-id pub-id-type="pmid">17552026</pub-id>
</element-citation></ref><ref id="B6-viruses-17-00163"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ioannou</surname><given-names>G.N.</given-names></name>
<name><surname>Feld</surname><given-names>J.J.</given-names></name>
</person-group><article-title>What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?</article-title><source>Gastroenterology</source><year>2019</year><volume>156</volume><fpage>446</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.10.033</pub-id><pub-id pub-id-type="pmid">30367836</pub-id>
</element-citation></ref><ref id="B7-viruses-17-00163"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shiratori</surname><given-names>Y.</given-names></name>
<name><surname>Ito</surname><given-names>Y.</given-names></name>
<name><surname>Yokosuka</surname><given-names>O.</given-names></name>
<name><surname>Imazeki</surname><given-names>F.</given-names></name>
<name><surname>Nakata</surname><given-names>R.</given-names></name>
<name><surname>Tanaka</surname><given-names>N.</given-names></name>
<name><surname>Arakawa</surname><given-names>Y.</given-names></name>
<name><surname>Hashimoto</surname><given-names>E.</given-names></name>
<name><surname>Hirota</surname><given-names>K.</given-names></name>
<name><surname>Yoshida</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival</article-title><source>Ann. Intern. Med.</source><year>2005</year><volume>142</volume><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-142-2-200501180-00009</pub-id><pub-id pub-id-type="pmid">15657158</pub-id>
</element-citation></ref><ref id="B8-viruses-17-00163"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dore</surname><given-names>G.J.</given-names></name>
<name><surname>Feld</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Hepatitis C virus therapeutic development: In pursuit of &#x0201c;perfectovir&#x0201d;</article-title><source>Clin. Infect. Dis.</source><year>2015</year><volume>60</volume><fpage>1829</fpage><lpage>1836</lpage><pub-id pub-id-type="doi">10.1093/cid/civ197</pub-id><pub-id pub-id-type="pmid">25761867</pub-id>
</element-citation></ref><ref id="B9-viruses-17-00163"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhattacharya</surname><given-names>D.</given-names></name>
<name><surname>Aronsohn</surname><given-names>A.</given-names></name>
<name><surname>Price</surname><given-names>J.</given-names></name>
<name><surname>Lo Re</surname><given-names>V.</given-names></name>
<collab>AASLD-IDSA HCV Guidance Panel</collab>
</person-group><article-title>Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection</article-title><source>Clin. Infect. Dis.</source><year>2023</year><volume>2023</volume><fpage>ciad319</fpage><pub-id pub-id-type="doi">10.1093/cid/ciad319</pub-id></element-citation></ref><ref id="B10-viruses-17-00163"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>European Association for the Study of the Liver</collab>
</person-group><article-title>EASL recommendations on treatment of hepatitis C: Final update of the series</article-title><source>J. Hepatol.</source><year>2020</year><volume>73</volume><fpage>1170</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.08.018</pub-id><pub-id pub-id-type="pmid">32956768</pub-id>
</element-citation></ref><ref id="B11-viruses-17-00163"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoofnagle</surname><given-names>J.H.</given-names></name>
<name><surname>Mullen</surname><given-names>K.D.</given-names></name>
<name><surname>Jones</surname><given-names>D.B.</given-names></name>
<name><surname>Rustgi</surname><given-names>V.</given-names></name>
<name><surname>Di Bisceglie</surname><given-names>A.</given-names></name>
<name><surname>Peters</surname><given-names>M.</given-names></name>
<name><surname>Waggoner</surname><given-names>J.G.</given-names></name>
<name><surname>Park</surname><given-names>Y.</given-names></name>
<name><surname>Jones</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report</article-title><source>N. Engl. J. Med.</source><year>1986</year><volume>315</volume><fpage>1575</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1056/NEJM198612183152503</pub-id><pub-id pub-id-type="pmid">3097544</pub-id>
</element-citation></ref><ref id="B12-viruses-17-00163"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samuel</surname><given-names>C.E.</given-names></name>
</person-group><article-title>Antiviral actions of interferons</article-title><source>Clin. Microbiol. Rev.</source><year>2001</year><volume>14</volume><fpage>778</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1128/CMR.14.4.778-809.2001</pub-id><pub-id pub-id-type="pmid">11585785</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00163"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Bisceglie</surname><given-names>A.M.</given-names></name>
<name><surname>Martin</surname><given-names>P.</given-names></name>
<name><surname>Kassianides</surname><given-names>C.</given-names></name>
<name><surname>Lisker-Melman</surname><given-names>M.</given-names></name>
<name><surname>Murray</surname><given-names>L.</given-names></name>
<name><surname>Waggoner</surname><given-names>J.</given-names></name>
<name><surname>Goodman</surname><given-names>Z.</given-names></name>
<name><surname>Banks</surname><given-names>S.M.</given-names></name>
<name><surname>Hoofnagle</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial</article-title><source>N. Engl. J. Med.</source><year>1989</year><volume>321</volume><fpage>1506</fpage><pub-id pub-id-type="doi">10.1056/NEJM198911303212204</pub-id><pub-id pub-id-type="pmid">2509917</pub-id>
</element-citation></ref><ref id="B14-viruses-17-00163"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davis</surname><given-names>G.L.</given-names></name>
<name><surname>Balart</surname><given-names>L.A.</given-names></name>
<name><surname>Schiff</surname><given-names>E.R.</given-names></name>
<name><surname>Lindsay</surname><given-names>K.</given-names></name>
<name><surname>Bodenheimer</surname><given-names>H.C.</given-names></name>
<name><surname>Perrillo</surname><given-names>R.P.</given-names></name>
<name><surname>Carey</surname><given-names>W.</given-names></name>
<name><surname>Jacobson</surname><given-names>I.M.</given-names></name>
<name><surname>Payne</surname><given-names>J.</given-names></name>
<name><surname>Dienstag</surname><given-names>J.L.</given-names></name>
<etal/>
</person-group><article-title>Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial</article-title><source>N. Engl. J. Med.</source><year>1989</year><volume>321</volume><fpage>1501</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1056/NEJM198911303212203</pub-id><pub-id pub-id-type="pmid">2509916</pub-id>
</element-citation></ref><ref id="B15-viruses-17-00163"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davis</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Recombinant alpha-interferon treatment of non-A, and non-B (type C) hepatitis: Review of studies and recommendations for treatment</article-title><source>J. Hepatol.</source><year>1990</year><volume>11</volume><issue>(Suppl. S1)</issue><fpage>S72</fpage><lpage>S77</lpage><pub-id pub-id-type="doi">10.1016/0168-8278(90)90168-Q</pub-id><pub-id pub-id-type="pmid">2127792</pub-id>
</element-citation></ref><ref id="B16-viruses-17-00163"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dusheiko</surname><given-names>G.</given-names></name>
</person-group><article-title>Side effects of alpha interferon in chronic hepatitis C</article-title><source>Hepatology</source><year>1997</year><volume>26</volume><issue>(Suppl. S1)</issue><fpage>112S</fpage><lpage>121S</lpage><pub-id pub-id-type="doi">10.1002/hep.510260720</pub-id><pub-id pub-id-type="pmid">9305675</pub-id>
</element-citation></ref><ref id="B17-viruses-17-00163"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pawlotsky</surname><given-names>J.M.</given-names></name>
<name><surname>Germanidis</surname><given-names>G.</given-names></name>
<name><surname>Neumann</surname><given-names>A.U.</given-names></name>
<name><surname>Pellerin</surname><given-names>M.</given-names></name>
<name><surname>Frainais</surname><given-names>P.-O.</given-names></name>
<name><surname>Dhumeaux</surname><given-names>D.</given-names></name>
</person-group><article-title>Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations</article-title><source>J. Virol.</source><year>1998</year><volume>72</volume><fpage>2795</fpage><lpage>2805</lpage><pub-id pub-id-type="doi">10.1128/JVI.72.4.2795-2805.1998</pub-id><pub-id pub-id-type="pmid">9525599</pub-id>
</element-citation></ref><ref id="B18-viruses-17-00163"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>von Wagner</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>R&#x000fc;ster</surname><given-names>B.</given-names></name>
<name><surname>Kronenberger</surname><given-names>B.</given-names></name>
<name><surname>Sarrazin</surname><given-names>C.</given-names></name>
<name><surname>Roth</surname><given-names>W.K.</given-names></name>
<name><surname>Zeuzem</surname><given-names>S.</given-names></name>
</person-group><article-title>Dynamics of hepatitis C virus quasispecies turnover during interferon-alpha treatment</article-title><source>J. Viral Hepat.</source><year>2003</year><volume>10</volume><fpage>413</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2893.2003.00457.x</pub-id><pub-id pub-id-type="pmid">14633173</pub-id>
</element-citation></ref><ref id="B19-viruses-17-00163"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paterson</surname><given-names>M.</given-names></name>
<name><surname>Laxton</surname><given-names>C.</given-names></name>
<name><surname>Goldin</surname><given-names>R.D.</given-names></name>
<name><surname>Ackrill</surname><given-names>A.M.</given-names></name>
<name><surname>Foster</surname><given-names>G.R.</given-names></name>
</person-group><article-title>Selection of HCV NS5Aquasispecies during IFN therapy in patients with chronic HCV</article-title><source>Dig. Dis. Sci.</source><year>2001</year><volume>46</volume><fpage>1399</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1023/A:1010623417345</pub-id><pub-id pub-id-type="pmid">11478490</pub-id>
</element-citation></ref><ref id="B20-viruses-17-00163"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeuzem</surname><given-names>S.</given-names></name>
<name><surname>Heathcote</surname><given-names>J.E.</given-names></name>
<name><surname>Martin</surname><given-names>N.</given-names></name>
<name><surname>Nieforth</surname><given-names>K.</given-names></name>
<name><surname>Modi</surname><given-names>M.</given-names></name>
</person-group><article-title>Peginterferon alfa-2a (40 kDa) monotherapy: A novel agent for chronic hepatitis C therapy</article-title><source>Expert Opin. Investig. Drugs</source><year>2000</year><volume>10</volume><fpage>2201</fpage><lpage>2213</lpage></element-citation></ref><ref id="B21-viruses-17-00163"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeuzem</surname><given-names>S.</given-names></name>
<name><surname>Welsch</surname><given-names>C.</given-names></name>
<name><surname>Herrmann</surname><given-names>E.</given-names></name>
</person-group><article-title>Pharmacokinetics of peginterferons</article-title><source>Semin. Liver Dis.</source><year>2003</year><volume>23</volume><issue>(Suppl. S1)</issue><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1055/s-2003-41631</pub-id><pub-id pub-id-type="pmid">12934165</pub-id>
</element-citation></ref><ref id="B22-viruses-17-00163"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zaman</surname><given-names>A.</given-names></name>
<name><surname>Fennerty</surname><given-names>M.B.</given-names></name>
<name><surname>Keeffe</surname><given-names>E.B.</given-names></name>
</person-group><article-title>Systematic review: Peginterferon vs. standard interferon in the treatment of chronic hepatitis C</article-title><source>Aliment. Pharmacol. Ther.</source><year>2003</year><volume>18</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2003.01747.x</pub-id><pub-id pub-id-type="pmid">14510739</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00163"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pockros</surname><given-names>P.J.</given-names></name>
<name><surname>Carithers</surname><given-names>R.</given-names></name>
<name><surname>Desmond</surname><given-names>P.</given-names></name>
<name><surname>Dhumeaux</surname><given-names>D.</given-names></name>
<name><surname>Fried</surname><given-names>M.W.</given-names></name>
<name><surname>Marcellin</surname><given-names>P.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.L.</given-names></name>
<name><surname>Minuk</surname><given-names>G.</given-names></name>
<name><surname>Reddy</surname><given-names>K.R.</given-names></name>
<name><surname>Reindollar</surname><given-names>R.W.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: A multicenter, randomized controlled trial</article-title><source>Am. J. Gastroenterol.</source><year>2004</year><volume>99</volume><fpage>1298</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2004.30306.x</pub-id><pub-id pub-id-type="pmid">15233669</pub-id>
</element-citation></ref><ref id="B24-viruses-17-00163"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lurie</surname><given-names>Y.</given-names></name>
<name><surname>Rouzier-Panis</surname><given-names>R.</given-names></name>
<name><surname>Webster</surname><given-names>G.J.</given-names></name>
<name><surname>Dusheiko</surname><given-names>G.M.</given-names></name>
<name><surname>Laughlin</surname><given-names>M.</given-names></name>
<name><surname>Jackson</surname><given-names>M.L.</given-names></name>
<name><surname>Oren</surname><given-names>R.</given-names></name>
</person-group><article-title>Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2005</year><volume>3</volume><fpage>610</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/S1542-3565(04)00723-2</pub-id><pub-id pub-id-type="pmid">15952104</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00163"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamal</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Improving outcome in patients with hepatitis C virus genotype 4</article-title><source>Am. J. Gastroenterol.</source><year>2007</year><volume>102</volume><fpage>2582</fpage><lpage>2588</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2007.01538.x</pub-id><pub-id pub-id-type="pmid">17900328</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00163"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamal</surname><given-names>S.M.</given-names></name>
<name><surname>Kassim</surname><given-names>S.K.</given-names></name>
<name><surname>Ahmed</surname><given-names>A.I.</given-names></name>
<name><surname>Mahmoud</surname><given-names>S.</given-names></name>
<name><surname>A Bahnasy</surname><given-names>K.</given-names></name>
<name><surname>A Hafez</surname><given-names>T.</given-names></name>
<name><surname>Aziz</surname><given-names>I.A.</given-names></name>
<name><surname>Fathelbab</surname><given-names>I.F.</given-names></name>
<name><surname>Mansour</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Host and viral determinants of the outcome of exposure to HCV infection genotype 4: A large longitudinal study</article-title><source>Am. J. Gastroenterol.</source><year>2014</year><volume>109</volume><fpage>199</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1038/ajg.2013.427</pub-id><pub-id pub-id-type="pmid">24445571</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00163"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yada</surname><given-names>M.</given-names></name>
<name><surname>Masumoto</surname><given-names>A.</given-names></name>
<name><surname>Yamashita</surname><given-names>N.</given-names></name>
<name><surname>Motomura</surname><given-names>K.</given-names></name>
<name><surname>Koyanagi</surname><given-names>T.</given-names></name>
<name><surname>Sakamoto</surname><given-names>S.</given-names></name>
</person-group><article-title>Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C</article-title><source>World J. Gastroenterol.</source><year>2010</year><volume>16</volume><fpage>1506</fpage><lpage>1511</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i12.1506</pub-id><pub-id pub-id-type="pmid">20333792</pub-id>
</element-citation></ref><ref id="B28-viruses-17-00163"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawaoka</surname><given-names>T.</given-names></name>
<name><surname>Hayes</surname><given-names>C.N.</given-names></name>
<name><surname>Ohishi</surname><given-names>W.</given-names></name>
<name><surname>Ochi</surname><given-names>H.</given-names></name>
<name><surname>Maekawa</surname><given-names>T.</given-names></name>
<name><surname>Abe</surname><given-names>H.</given-names></name>
<name><surname>Tsuge</surname><given-names>M.</given-names></name>
<name><surname>Mitsui</surname><given-names>F.</given-names></name>
<name><surname>Hiraga</surname><given-names>N.</given-names></name>
<name><surname>Imamura</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b</article-title><source>J. Hepatol.</source><year>2011</year><volume>54</volume><fpage>408</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.07.032</pub-id><pub-id pub-id-type="pmid">21112660</pub-id>
</element-citation></ref><ref id="B29-viruses-17-00163"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ochi</surname><given-names>H.</given-names></name>
<name><surname>Maekawa</surname><given-names>T.</given-names></name>
<name><surname>Abe</surname><given-names>H.</given-names></name>
<name><surname>Hayashida</surname><given-names>Y.</given-names></name>
<name><surname>Nakano</surname><given-names>R.</given-names></name>
<name><surname>Imamura</surname><given-names>M.</given-names></name>
<name><surname>Hiraga</surname><given-names>N.</given-names></name>
<name><surname>Kawakami</surname><given-names>Y.</given-names></name>
<name><surname>Aimitsu</surname><given-names>S.</given-names></name>
<name><surname>Kao</surname><given-names>J.-H.</given-names></name>
<etal/>
</person-group><article-title>IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations</article-title><source>J. Gen. Virol.</source><year>2011</year><volume>92</volume><fpage>1071</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1099/vir.0.029124-0</pub-id><pub-id pub-id-type="pmid">21228123</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00163"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
<name><surname>Fried</surname><given-names>M.W.</given-names></name>
</person-group><article-title>Current therapy for hepatitis C: Pegylated interferon and ribavirin</article-title><source>Clin. Liver Dis.</source><year>2003</year><volume>7</volume><fpage>149</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/S1089-3261(02)00077-6</pub-id><pub-id pub-id-type="pmid">12691464</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00163"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Te</surname><given-names>H.S.</given-names></name>
<name><surname>Randall</surname><given-names>G.</given-names></name>
<name><surname>Jensen</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Mechanism of action of ribavirin in the treatment of chronic hepatitis C</article-title><source>Gastroenterol. Hepatol.</source><year>2007</year><volume>3</volume><fpage>218</fpage><lpage>225</lpage></element-citation></ref><ref id="B32-viruses-17-00163"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feld</surname><given-names>J.J.</given-names></name>
<name><surname>Hoofnagle</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Mechanism of action of interferon and ribavirin in treatment of hepatitis C</article-title><source>Nature</source><year>2005</year><volume>436</volume><fpage>967</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1038/nature04082</pub-id><pub-id pub-id-type="pmid">16107837</pub-id>
</element-citation></ref><ref id="B33-viruses-17-00163"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Schiff</surname><given-names>E.R.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.L.</given-names></name>
<name><surname>Lee</surname><given-names>W.M.</given-names></name>
<name><surname>Rustgi</surname><given-names>V.K.</given-names></name>
<name><surname>Goodman</surname><given-names>Z.D.</given-names></name>
<name><surname>Ling</surname><given-names>M.-H.</given-names></name>
<name><surname>Cort</surname><given-names>S.</given-names></name>
<name><surname>Albrecht</surname><given-names>J.K.</given-names></name>
</person-group><article-title>Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group</article-title><source>N. Engl. J. Med.</source><year>1998</year><volume>339</volume><fpage>1485</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1056/NEJM199811193392101</pub-id><pub-id pub-id-type="pmid">9819446</pub-id>
</element-citation></ref><ref id="B34-viruses-17-00163"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poynard</surname><given-names>T.</given-names></name>
<name><surname>Marcellin</surname><given-names>P.</given-names></name>
<name><surname>Lee</surname><given-names>S.S.</given-names></name>
<name><surname>Niederau</surname><given-names>C.</given-names></name>
<name><surname>Minuk</surname><given-names>G.S.</given-names></name>
<name><surname>Ideo</surname><given-names>G.</given-names></name>
<name><surname>Bain</surname><given-names>V.</given-names></name>
<name><surname>Heathcote</surname><given-names>J.</given-names></name>
<name><surname>Zeuzem</surname><given-names>S.</given-names></name>
<name><surname>Trepo</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>1426</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(98)07124-4</pub-id><pub-id pub-id-type="pmid">9807989</pub-id>
</element-citation></ref><ref id="B35-viruses-17-00163"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lindsay</surname><given-names>K.L.</given-names></name>
<name><surname>Trepo</surname><given-names>C.</given-names></name>
<name><surname>Heintges</surname><given-names>T.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.L.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Hoefs</surname><given-names>J.C.</given-names></name>
<name><surname>Schiff</surname><given-names>E.R.</given-names></name>
<name><surname>Goodman</surname><given-names>Z.D.</given-names></name>
<name><surname>Laughlin</surname><given-names>M.</given-names></name>
<name><surname>Yao</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>A randomized double- blind trial comparing pegylated interferon alfa-2b to inter-feron alfa-2b as initial treatment for chronic hepatitis C</article-title><source>Hepatology</source><year>2001</year><volume>34</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1053/jhep.2001.26371</pub-id><pub-id pub-id-type="pmid">11481625</pub-id>
</element-citation></ref><ref id="B36-viruses-17-00163"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeuzem</surname><given-names>S.</given-names></name>
<name><surname>Feinman</surname><given-names>S.V.</given-names></name>
<name><surname>Rasenack</surname><given-names>J.</given-names></name>
<name><surname>Heathcote</surname><given-names>E.J.</given-names></name>
<name><surname>Lai</surname><given-names>M.-Y.</given-names></name>
<name><surname>Gane</surname><given-names>E.</given-names></name>
<name><surname>O&#x02019;Grady</surname><given-names>J.</given-names></name>
<name><surname>Reichen</surname><given-names>J.</given-names></name>
<name><surname>Diago</surname><given-names>M.</given-names></name>
<name><surname>Lin</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Peginterferon alfa- 2a in patients with chronic hepatitis C</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>343</volume><fpage>1666</fpage><lpage>1672</lpage><pub-id pub-id-type="doi">10.1056/NEJM200012073432301</pub-id><pub-id pub-id-type="pmid">11106715</pub-id>
</element-citation></ref><ref id="B37-viruses-17-00163"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heathcote</surname><given-names>E.J.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.L.</given-names></name>
<name><surname>Cooksley</surname><given-names>W.G.E.</given-names></name>
<name><surname>Dusheiko</surname><given-names>G.M.</given-names></name>
<name><surname>Lee</surname><given-names>S.S.</given-names></name>
<name><surname>Balart</surname><given-names>L.</given-names></name>
<name><surname>Reindollar</surname><given-names>R.</given-names></name>
<name><surname>Reddy</surname><given-names>R.K.</given-names></name>
<name><surname>Wright</surname><given-names>T.L.</given-names></name>
<name><surname>Lin</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>343</volume><fpage>1673</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1056/NEJM200012073432302</pub-id><pub-id pub-id-type="pmid">11106716</pub-id>
</element-citation></ref><ref id="B38-viruses-17-00163"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manns</surname><given-names>M.P.</given-names></name>
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Rustgi</surname><given-names>V.K.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.</given-names></name>
<name><surname>Reindollar</surname><given-names>R.</given-names></name>
<name><surname>Goodman</surname><given-names>Z.D.</given-names></name>
<name><surname>Koury</surname><given-names>K.</given-names></name>
<name><surname>Ling</surname><given-names>M.-H.</given-names></name>
<name><surname>Albrecht</surname><given-names>J.K.</given-names></name>
</person-group><article-title>Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial</article-title><source>Lancet</source><year>2001</year><volume>358</volume><fpage>958</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(01)06102-5</pub-id><pub-id pub-id-type="pmid">11583749</pub-id>
</element-citation></ref><ref id="B39-viruses-17-00163"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fried</surname><given-names>M.W.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.L.</given-names></name>
<name><surname>Reddy</surname><given-names>K.R.</given-names></name>
<name><surname>Smith</surname><given-names>C.</given-names></name>
<name><surname>Marinos</surname><given-names>G.</given-names></name>
<name><surname>Gon&#x000e7;ales</surname><given-names>F.L.J.</given-names></name>
<name><surname>H&#x000e4;ussinger</surname><given-names>D.</given-names></name>
<name><surname>Diago</surname><given-names>M.</given-names></name>
<name><surname>Carosi</surname><given-names>G.</given-names></name>
<name><surname>Dhumeaux</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection</article-title><source>N. Engl. J. Med.</source><year>2002</year><volume>347</volume><fpage>975</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa020047</pub-id><pub-id pub-id-type="pmid">12324553</pub-id>
</element-citation></ref><ref id="B40-viruses-17-00163"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamal</surname><given-names>S.M.</given-names></name>
<name><surname>El Kamary</surname><given-names>S.S.</given-names></name>
<name><surname>Shardell</surname><given-names>M.D.</given-names></name>
<name><surname>Hashem</surname><given-names>M.</given-names></name>
<name><surname>Ahmed</surname><given-names>I.N.</given-names></name>
<name><surname>Muhammadi</surname><given-names>M.</given-names></name>
<name><surname>Sayed</surname><given-names>K.</given-names></name>
<name><surname>Moustafa</surname><given-names>A.</given-names></name>
<name><surname>Hakem</surname><given-names>S.A.</given-names></name>
<name><surname>Ibrahiem</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response</article-title><source>Hepatology</source><year>2007</year><volume>46</volume><fpage>1732</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1002/hep.21917</pub-id><pub-id pub-id-type="pmid">17943989</pub-id>
</element-citation></ref><ref id="B41-viruses-17-00163"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.J.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.L.</given-names></name>
<name><surname>Muir</surname><given-names>A.J.</given-names></name>
<name><surname>Galler</surname><given-names>G.W.</given-names></name>
<name><surname>McCone</surname><given-names>J.</given-names></name>
<name><surname>Nyberg</surname><given-names>L.M.</given-names></name>
<name><surname>Lee</surname><given-names>W.M.</given-names></name>
<name><surname>Ghalib</surname><given-names>R.H.</given-names></name>
<name><surname>Schiff</surname><given-names>E.R.</given-names></name>
<etal/>
</person-group><article-title>Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>361</volume><fpage>580</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0808010</pub-id><pub-id pub-id-type="pmid">19625712</pub-id>
</element-citation></ref><ref id="B42-viruses-17-00163"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kowdley</surname><given-names>K.V.</given-names></name>
</person-group><article-title>Hematologic side effects of interferon and ribavirin therapy</article-title><source>J. Clin. Gastroenterol.</source><year>2005</year><volume>39</volume><issue>(Suppl. S1)</issue><fpage>S3</fpage><lpage>S8</lpage><pub-id pub-id-type="doi">10.1097/01.mcg.0000145494.76305.11</pub-id><pub-id pub-id-type="pmid">15597025</pub-id>
</element-citation></ref><ref id="B43-viruses-17-00163"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minami</surname><given-names>T.</given-names></name>
<name><surname>Kishikawa</surname><given-names>T.</given-names></name>
<name><surname>Sato</surname><given-names>M.</given-names></name>
<name><surname>Tateishi</surname><given-names>R.</given-names></name>
<name><surname>Yoshida</surname><given-names>H.</given-names></name>
<name><surname>Koike</surname><given-names>K.</given-names></name>
</person-group><article-title>Meta-analysis:mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C</article-title><source>J. Gastroenterol.</source><year>2013</year><volume>48</volume><fpage>254</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1007/s00535-012-0631-y</pub-id><pub-id pub-id-type="pmid">22790350</pub-id>
</element-citation></ref><ref id="B44-viruses-17-00163"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Udina</surname><given-names>M.</given-names></name>
<name><surname>Castellv&#x000ed;</surname><given-names>P.</given-names></name>
<name><surname>Moreno-Espa&#x000f1;a</surname><given-names>J.</given-names></name>
<name><surname>Navin&#x000e9;s</surname><given-names>R.</given-names></name>
<name><surname>Vald&#x000e9;s</surname><given-names>M.</given-names></name>
<name><surname>Forns</surname><given-names>X.</given-names></name>
<name><surname>Langohr</surname><given-names>K.</given-names></name>
<name><surname>Sol&#x000e0;</surname><given-names>R.</given-names></name>
<name><surname>Vieta</surname><given-names>E.</given-names></name>
<name><surname>Mart&#x000ed;n-Santos</surname><given-names>R.</given-names></name>
</person-group><article-title>Interferon-induced depression in chronic hepatitis C: A systematic review and meta-analysis</article-title><source>J. Clin. Psychiatry</source><year>2012</year><volume>73</volume><fpage>1128</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.4088/JCP.12r07694</pub-id><pub-id pub-id-type="pmid">22967776</pub-id>
</element-citation></ref><ref id="B45-viruses-17-00163"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lam</surname><given-names>J.T.</given-names></name>
<name><surname>Jacob</surname><given-names>S.</given-names></name>
</person-group><article-title>Boceprevir: A recently approved protease inhibitor for hepatitis C virus infection</article-title><source>Am. J. Health Syst. Pharm.</source><year>2012</year><volume>69</volume><fpage>2135</fpage><lpage>2139</lpage><pub-id pub-id-type="doi">10.2146/ajhp110500</pub-id><pub-id pub-id-type="pmid">23230035</pub-id>
</element-citation></ref><ref id="B46-viruses-17-00163"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muir</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Telaprevir for the treatment of chronic hepatitis C infection</article-title><source>Expert Rev. Anti-Infect. Ther.</source><year>2011</year><volume>9</volume><fpage>1105</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1586/eri.11.133</pub-id><pub-id pub-id-type="pmid">22114960</pub-id>
</element-citation></ref><ref id="B47-viruses-17-00163"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klibanov</surname><given-names>O.M.</given-names></name>
<name><surname>Vickery</surname><given-names>S.B.</given-names></name>
<name><surname>Olin</surname><given-names>J.L.</given-names></name>
<name><surname>Smith</surname><given-names>L.S.</given-names></name>
<name><surname>Williams</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Boceprevir: A novel NS3/4 protease inhibitor for the treatment of hepatitis C</article-title><source>Pharmacotherapy</source><year>2012</year><volume>32</volume><fpage>173</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1002/PHAR.1046</pub-id><pub-id pub-id-type="pmid">22392426</pub-id>
</element-citation></ref><ref id="B48-viruses-17-00163"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>L.S.</given-names></name>
<name><surname>Nelson</surname><given-names>M.</given-names></name>
<name><surname>Naik</surname><given-names>S.</given-names></name>
<name><surname>Woten</surname><given-names>J.</given-names></name>
</person-group><article-title>Telaprevir: An NS3/4A protease inhibitor for the treatment of chronic hepatitis C</article-title><source>Ann. Pharmacother.</source><year>2011</year><volume>45</volume><fpage>639</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1345/aph.1P430</pub-id><pub-id pub-id-type="pmid">21558488</pub-id>
</element-citation></ref><ref id="B49-viruses-17-00163"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jacobson</surname><given-names>I.M.</given-names></name>
<name><surname>Pawlotsky</surname><given-names>J.M.</given-names></name>
<name><surname>Afdhal</surname><given-names>N.H.</given-names></name>
<name><surname>Dusheiko</surname><given-names>G.M.</given-names></name>
<name><surname>Forns</surname><given-names>X.</given-names></name>
<name><surname>Jensen</surname><given-names>D.M.</given-names></name>
<name><surname>Poordad</surname><given-names>F.</given-names></name>
<name><surname>Schulz</surname><given-names>J.</given-names></name>
</person-group><article-title>A practical guide for the use of boceprevir telaprevir for the treatment of hepatitis C</article-title><source>J. Viral Hepat.</source><year>2012</year><volume>19</volume><issue>(Suppl. S2)</issue><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2012.01590.x</pub-id></element-citation></ref><ref id="B50-viruses-17-00163"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
<name><surname>Everson</surname><given-names>G.T.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Jacobson</surname><given-names>I.M.</given-names></name>
<name><surname>Sulkowski</surname><given-names>M.</given-names></name>
<name><surname>Kauffman</surname><given-names>R.</given-names></name>
<name><surname>McNair</surname><given-names>L.</given-names></name>
<name><surname>Alam</surname><given-names>J.</given-names></name>
<name><surname>Muir</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>360</volume><fpage>1827</fpage><lpage>1838</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0806104</pub-id><pub-id pub-id-type="pmid">19403902</pub-id>
</element-citation></ref><ref id="B51-viruses-17-00163"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>H&#x000e9;zode</surname><given-names>C.</given-names></name>
<name><surname>Forestier</surname><given-names>N.</given-names></name>
<name><surname>Dusheiko</surname><given-names>G.</given-names></name>
<name><surname>Ferenci</surname><given-names>P.</given-names></name>
<name><surname>Pol</surname><given-names>S.</given-names></name>
<name><surname>Goeser</surname><given-names>T.</given-names></name>
<name><surname>Bronowicki</surname><given-names>J.-P.</given-names></name>
<name><surname>Bourli&#x000e8;re</surname><given-names>M.</given-names></name>
<name><surname>Gharakhanian</surname><given-names>S.</given-names></name>
<name><surname>Bengtsson</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Telaprevir and peginterferon with or without ribavirin for chronic HCV infection</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>360</volume><fpage>1839</fpage><lpage>1850</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0807650</pub-id><pub-id pub-id-type="pmid">19403903</pub-id>
</element-citation></ref><ref id="B52-viruses-17-00163"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
<name><surname>Manns</surname><given-names>M.P.</given-names></name>
<name><surname>Muir</surname><given-names>A.J.</given-names></name>
<name><surname>Terrault</surname><given-names>N.A.</given-names></name>
<name><surname>Jacobson</surname><given-names>I.M.</given-names></name>
<name><surname>Afdhal</surname><given-names>N.H.</given-names></name>
<name><surname>Heathcote</surname><given-names>E.J.</given-names></name>
<name><surname>Zeuzem</surname><given-names>S.</given-names></name>
<name><surname>Reesink</surname><given-names>H.W.</given-names></name>
<name><surname>Garg</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Telaprevir for previously treated chronic HCV infection</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>362</volume><fpage>1292</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0908014</pub-id><pub-id pub-id-type="pmid">20375406</pub-id>
</element-citation></ref><ref id="B53-viruses-17-00163"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jacobson</surname><given-names>I.M.</given-names></name>
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
<name><surname>Dusheiko</surname><given-names>G.</given-names></name>
<name><surname>Di Bisceglie</surname><given-names>A.M.</given-names></name>
<name><surname>Reddy</surname><given-names>K.R.</given-names></name>
<name><surname>Bzowej</surname><given-names>N.H.</given-names></name>
<name><surname>Marcellin</surname><given-names>P.</given-names></name>
<name><surname>Muir</surname><given-names>A.J.</given-names></name>
<name><surname>Ferenci</surname><given-names>P.</given-names></name>
<name><surname>Flisiak</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Telaprevir for previously untreated chronic hepatitis C virus infection</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>364</volume><fpage>2405</fpage><lpage>2416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1012912</pub-id><pub-id pub-id-type="pmid">21696307</pub-id>
</element-citation></ref><ref id="B54-viruses-17-00163"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeuzem</surname><given-names>S.</given-names></name>
<name><surname>Andreone</surname><given-names>P.</given-names></name>
<name><surname>Pol</surname><given-names>S.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Diago</surname><given-names>M.</given-names></name>
<name><surname>Roberts</surname><given-names>S.</given-names></name>
<name><surname>Focaccia</surname><given-names>R.</given-names></name>
<name><surname>Younossi</surname><given-names>Z.</given-names></name>
<name><surname>Foster</surname><given-names>G.R.</given-names></name>
<name><surname>Horban</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Telaprevir for retreatment of HCV infection</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>364</volume><fpage>2417</fpage><lpage>2428</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1013086</pub-id><pub-id pub-id-type="pmid">21696308</pub-id>
</element-citation></ref><ref id="B55-viruses-17-00163"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwo</surname><given-names>P.Y.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.J.</given-names></name>
<name><surname>McCone</surname><given-names>J.</given-names></name>
<name><surname>Schiff</surname><given-names>E.R.</given-names></name>
<name><surname>Vierling</surname><given-names>J.M.</given-names></name>
<name><surname>Pound</surname><given-names>D.</given-names></name>
<name><surname>Davis</surname><given-names>M.N.</given-names></name>
<name><surname>Galati</surname><given-names>J.S.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Ravendhran</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><fpage>705</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60934-8</pub-id><pub-id pub-id-type="pmid">20692693</pub-id>
</element-citation></ref><ref id="B56-viruses-17-00163"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poordad</surname><given-names>F.</given-names></name>
<name><surname>McCone</surname><given-names>J.</given-names><suffix>Jr.</suffix></name>
<name><surname>Bacon</surname><given-names>B.R.</given-names></name>
<name><surname>Bruno</surname><given-names>S.</given-names></name>
<name><surname>Manns</surname><given-names>M.P.</given-names></name>
<name><surname>Sulkowski</surname><given-names>M.S.</given-names></name>
<name><surname>Jacobson</surname><given-names>I.M.</given-names></name>
<name><surname>Reddy</surname><given-names>K.R.</given-names></name>
<name><surname>Goodman</surname><given-names>Z.D.</given-names></name>
<name><surname>Boparai</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Boceprevir for untreated chronic HCV genotype 1 infection</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>364</volume><fpage>1195</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1010494</pub-id><pub-id pub-id-type="pmid">21449783</pub-id>
</element-citation></ref><ref id="B57-viruses-17-00163"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bacon</surname><given-names>B.R.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Marcellin</surname><given-names>P.</given-names></name>
<name><surname>Vierling</surname><given-names>J.M.</given-names></name>
<name><surname>Zeuzem</surname><given-names>S.</given-names></name>
<name><surname>Poordad</surname><given-names>F.</given-names></name>
<name><surname>Goodman</surname><given-names>Z.D.</given-names></name>
<name><surname>Sings</surname><given-names>H.L.</given-names></name>
<name><surname>Boparai</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Boceprevir for previously treated chronic HCV genotype 1 infection</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>364</volume><fpage>1207</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1009482</pub-id><pub-id pub-id-type="pmid">21449784</pub-id>
</element-citation></ref><ref id="B58-viruses-17-00163"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarrazin</surname><given-names>C.</given-names></name>
</person-group><article-title>The importance of resistance to direct antiviral drugs in HCV infection in clinical practice</article-title><source>J. Hepatol.</source><year>2016</year><volume>64</volume><fpage>486</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.09.011</pub-id><pub-id pub-id-type="pmid">26409317</pub-id>
</element-citation></ref><ref id="B59-viruses-17-00163"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>H&#x000e9;zode</surname><given-names>C.</given-names></name>
</person-group><article-title>Boceprevir and telaprevir for the treatment of chronic hepatitis C: Safety management in clinical practice</article-title><source>Liver Int.</source><year>2012</year><volume>32</volume><issue>(Suppl. S1)</issue><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2011.02707.x</pub-id><pub-id pub-id-type="pmid">22212569</pub-id>
</element-citation></ref><ref id="B60-viruses-17-00163"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>P.</given-names></name>
<name><surname>Malik</surname><given-names>K.</given-names></name>
<name><surname>Krishnamurthy</surname><given-names>K.</given-names></name>
</person-group><article-title>Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated with New Direct-Acting Antivirals: A Systematic Review and Meta-Analysis</article-title><source>J. Cutan. Med. Surg.</source><year>2016</year><volume>20</volume><fpage>58</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1177/1203475415595775</pub-id><pub-id pub-id-type="pmid">26162860</pub-id>
</element-citation></ref><ref id="B61-viruses-17-00163"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mauss</surname><given-names>S.</given-names></name>
<name><surname>Hueppe</surname><given-names>D.</given-names></name>
<name><surname>Alshuth</surname><given-names>U.</given-names></name>
</person-group><article-title>Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir</article-title><source>Hepatology</source><year>2014</year><volume>59</volume><fpage>46</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/hep.26602</pub-id><pub-id pub-id-type="pmid">23813604</pub-id>
</element-citation></ref><ref id="B62-viruses-17-00163"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Back</surname><given-names>D.</given-names></name>
<name><surname>Else</surname><given-names>L.</given-names></name>
</person-group><article-title>The importance of drug-drug interactions in the DAA era</article-title><source>Dig. Liver Dis.</source><year>2013</year><volume>45</volume><issue>(Suppl. S5)</issue><fpage>S343</fpage><lpage>S348</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2013.07.008</pub-id><pub-id pub-id-type="pmid">24091114</pub-id>
</element-citation></ref><ref id="B63-viruses-17-00163"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Talavera Pons</surname><given-names>S.</given-names></name>
<name><surname>Lamblin</surname><given-names>G.</given-names></name>
<name><surname>Boyer</surname><given-names>A.</given-names></name>
<name><surname>Sautou</surname><given-names>V.</given-names></name>
<name><surname>Abergel</surname><given-names>A.</given-names></name>
</person-group><article-title>Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2014</year><volume>70</volume><fpage>775</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1007/s00228-014-1679-9</pub-id><pub-id pub-id-type="pmid">24817413</pub-id>
</element-citation></ref><ref id="B64-viruses-17-00163"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burger</surname><given-names>D.</given-names></name>
<name><surname>Back</surname><given-names>D.</given-names></name>
<name><surname>Buggisch</surname><given-names>P.</given-names></name>
<name><surname>Buti</surname><given-names>M.</given-names></name>
<name><surname>Crax&#x000ed;</surname><given-names>A.</given-names></name>
<name><surname>Foster</surname><given-names>G.</given-names></name>
<name><surname>Klinker</surname><given-names>H.</given-names></name>
<name><surname>Larrey</surname><given-names>D.</given-names></name>
<name><surname>Nikitin</surname><given-names>I.</given-names></name>
<name><surname>Pol</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions</article-title><source>J. Hepatol.</source><year>2013</year><volume>58</volume><fpage>792</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2012.10.027</pub-id><pub-id pub-id-type="pmid">23137766</pub-id>
</element-citation></ref><ref id="B65-viruses-17-00163"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kiser</surname><given-names>J.J.</given-names></name>
<name><surname>Burton</surname><given-names>J.R.</given-names><suffix>Jr.</suffix></name>
<name><surname>Everson</surname><given-names>G.T.</given-names></name>
</person-group><article-title>Drug-drug interactions during antiviral therapy for chronic hepatitis C</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2013</year><volume>10</volume><fpage>596</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2013.106</pub-id><pub-id pub-id-type="pmid">23817323</pub-id>
</element-citation></ref><ref id="B66-viruses-17-00163"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pawlotsky</surname><given-names>J.M.</given-names></name>
</person-group><article-title>New hepatitis C therapies: The toolbox, strategies, and challenges</article-title><source>Gastroenterology</source><year>2014</year><volume>146</volume><fpage>1176</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.03.003</pub-id><pub-id pub-id-type="pmid">24631495</pub-id>
</element-citation></ref><ref id="B67-viruses-17-00163"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feeney</surname><given-names>E.R.</given-names></name>
<name><surname>Chung</surname><given-names>R.T.</given-names></name>
</person-group><article-title>Antiviral treatment of hepatitis C</article-title><source>BMJ</source><year>2014</year><volume>348</volume><fpage>g3308</fpage><pub-id pub-id-type="doi">10.1136/bmj.g3308</pub-id><pub-id pub-id-type="pmid">25002352</pub-id>
</element-citation></ref><ref id="B68-viruses-17-00163"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abraham</surname><given-names>G.M.</given-names></name>
<name><surname>Spooner</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Sofosbuvir in the treatment of chronic hepatitis C: New dog, new tricks</article-title><source>Clin. Infect. Dis.</source><year>2014</year><volume>59</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu265</pub-id><pub-id pub-id-type="pmid">24748524</pub-id>
</element-citation></ref><ref id="B69-viruses-17-00163"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feld</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Interferon-free strategies with a nucleoside/nucleotide analogue</article-title><source>Semin. Liver Dis.</source><year>2014</year><volume>34</volume><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1055/s-0034-1371009</pub-id><pub-id pub-id-type="pmid">24782257</pub-id>
</element-citation></ref><ref id="B70-viruses-17-00163"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noell</surname><given-names>B.C.</given-names></name>
<name><surname>Besur</surname><given-names>S.V.</given-names></name>
<name><surname>deLemos</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Changing the face of hepatitis C management&#x02014;The design and development of sofosbuvir</article-title><source>Drug Des. Dev. Ther.</source><year>2015</year><volume>9</volume><fpage>2367</fpage><lpage>2374</lpage></element-citation></ref><ref id="B71-viruses-17-00163"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gutierrez</surname><given-names>J.A.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.J.</given-names></name>
<name><surname>Poordad</surname><given-names>F.</given-names></name>
</person-group><article-title>Interferon-free, direct-acting antiviral therapy for chronic hepatitis C</article-title><source>J. Viral Hepat.</source><year>2015</year><volume>22</volume><fpage>861</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1111/jvh.12422</pub-id><pub-id pub-id-type="pmid">26083155</pub-id>
</element-citation></ref><ref id="B72-viruses-17-00163"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keating</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Ledipasvir/Sofosbuvir: A review of its use in chronic hepatitis C</article-title><source>Drugs</source><year>2015</year><volume>75</volume><fpage>675</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1007/s40265-015-0381-2</pub-id><pub-id pub-id-type="pmid">25837989</pub-id>
</element-citation></ref><ref id="B73-viruses-17-00163"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fourati</surname><given-names>S.</given-names></name>
<name><surname>Guedj</surname><given-names>J.</given-names></name>
<name><surname>Chevaliez</surname><given-names>S.</given-names></name>
<name><surname>Nguyen</surname><given-names>T.H.T.</given-names></name>
<name><surname>Roudot-Thoraval</surname><given-names>F.</given-names></name>
<name><surname>Ruiz</surname><given-names>I.</given-names></name>
<name><surname>Soulier</surname><given-names>A.</given-names></name>
<name><surname>Scoazec</surname><given-names>G.</given-names></name>
<name><surname>Varaut</surname><given-names>A.</given-names></name>
<name><surname>Poiteau</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor</article-title><source>Aliment. Pharmacol. Ther.</source><year>2018</year><volume>47</volume><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1111/apt.14478</pub-id><pub-id pub-id-type="pmid">29271114</pub-id>
</element-citation></ref><ref id="B74-viruses-17-00163"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buti</surname><given-names>M.</given-names></name>
<name><surname>Riveiro-Barciela</surname><given-names>M.</given-names></name>
<name><surname>Esteban</surname><given-names>R.</given-names></name>
</person-group><article-title>Management of direct-acting antiviral agent failures</article-title><source>J. Hepatol.</source><year>2015</year><volume>63</volume><fpage>1511</fpage><lpage>1522</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.08.010</pub-id><pub-id pub-id-type="pmid">26299621</pub-id>
</element-citation></ref><ref id="B75-viruses-17-00163"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cuenca-Lopez</surname><given-names>F.</given-names></name>
<name><surname>Rivero</surname><given-names>A.</given-names></name>
<name><surname>Rivero-Ju&#x000e1;rez</surname><given-names>A.</given-names></name>
</person-group><article-title>Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2017</year><volume>13</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1080/17425255.2017.1255725</pub-id><pub-id pub-id-type="pmid">27797596</pub-id>
</element-citation></ref><ref id="B76-viruses-17-00163"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uchida</surname><given-names>Y.</given-names></name>
<name><surname>Kouyama</surname><given-names>J.I.</given-names></name>
<name><surname>Naiki</surname><given-names>K.</given-names></name>
<name><surname>Sugawara</surname><given-names>K.</given-names></name>
<name><surname>Inao</surname><given-names>M.</given-names></name>
<name><surname>Imai</surname><given-names>Y.</given-names></name>
<name><surname>Nakayama</surname><given-names>N.</given-names></name>
<name><surname>Mochida</surname><given-names>S.</given-names></name>
</person-group><article-title>Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism</article-title><source>Hepatol. Res.</source><year>2016</year><volume>46</volume><fpage>1234</fpage><lpage>1246</lpage><pub-id pub-id-type="doi">10.1111/hepr.12673</pub-id><pub-id pub-id-type="pmid">26878268</pub-id>
</element-citation></ref><ref id="B77-viruses-17-00163"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pearlman</surname><given-names>B.L.</given-names></name>
<name><surname>Hinds</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Review article: Novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir</article-title><source>Aliment. Pharmacol. Ther.</source><year>2018</year><volume>48</volume><fpage>914</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1111/apt.14977</pub-id><pub-id pub-id-type="pmid">30288771</pub-id>
</element-citation></ref><ref id="B78-viruses-17-00163"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Mangia</surname><given-names>A.</given-names></name>
<name><surname>Wyles</surname><given-names>D.</given-names></name>
<name><surname>Rodriguez-Torres</surname><given-names>M.</given-names></name>
<name><surname>Hassanein</surname><given-names>T.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Schultz</surname><given-names>M.</given-names></name>
<name><surname>Davis</surname><given-names>M.N.</given-names></name>
<name><surname>Kayali</surname><given-names>Z.</given-names></name>
<name><surname>Reddy</surname><given-names>K.R.</given-names></name>
<etal/>
</person-group><article-title>Sofosbuvir for previously untreated chronic hepatitis C infection</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>1878</fpage><lpage>1887</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1214853</pub-id><pub-id pub-id-type="pmid">23607594</pub-id>
</element-citation></ref><ref id="B79-viruses-17-00163"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jacobson</surname><given-names>I.M.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Kowdley</surname><given-names>K.V.</given-names></name>
<name><surname>Yoshida</surname><given-names>E.M.</given-names></name>
<name><surname>Rodriguez-Torres</surname><given-names>M.</given-names></name>
<name><surname>Sulkowski</surname><given-names>M.S.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.L.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Everson</surname><given-names>G.</given-names></name>
<name><surname>Bennett</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>1867</fpage><lpage>1877</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1214854</pub-id><pub-id pub-id-type="pmid">23607593</pub-id>
</element-citation></ref><ref id="B80-viruses-17-00163"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Jacobson</surname><given-names>I.M.</given-names></name>
<name><surname>Nelson</surname><given-names>D.R.</given-names></name>
<name><surname>Zeuzem</surname><given-names>S.</given-names></name>
<name><surname>Sulkowski</surname><given-names>M.S.</given-names></name>
<name><surname>Esteban</surname><given-names>R.</given-names></name>
<name><surname>Brainard</surname><given-names>D.</given-names></name>
<name><surname>McNally</surname><given-names>J.</given-names></name>
<name><surname>Symonds</surname><given-names>W.T.</given-names></name>
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
<etal/>
</person-group><article-title>Development of sofosbuvir for the treatment of hepatitis C virus infection</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2015</year><volume>1358</volume><fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1111/nyas.12832</pub-id><pub-id pub-id-type="pmid">26235748</pub-id>
</element-citation></ref><ref id="B81-viruses-17-00163"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Younossi</surname><given-names>Z.M.</given-names></name>
<name><surname>Stepanova</surname><given-names>M.</given-names></name>
<name><surname>Nader</surname><given-names>F.</given-names></name>
<name><surname>Jacobson</surname><given-names>I.M.</given-names></name>
<name><surname>Gane</surname><given-names>E.</given-names></name>
<name><surname>Nelson</surname><given-names>D.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Hunt</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens</article-title><source>Hepatology</source><year>2014</year><volume>59</volume><fpage>2161</fpage><lpage>2169</lpage><pub-id pub-id-type="doi">10.1002/hep.27161</pub-id><pub-id pub-id-type="pmid">24710669</pub-id>
</element-citation></ref><ref id="B82-viruses-17-00163"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Curry</surname><given-names>M.P.</given-names></name>
<name><surname>Forns</surname><given-names>X.</given-names></name>
<name><surname>Chung</surname><given-names>R.T.</given-names></name>
<name><surname>Terrault</surname><given-names>N.A.</given-names></name>
<name><surname>Brown</surname><given-names>R.</given-names><suffix>Jr.</suffix></name>
<name><surname>Fenkel</surname><given-names>J.M.</given-names></name>
<name><surname>Gordon</surname><given-names>F.</given-names></name>
<name><surname>O&#x02019;Leary</surname><given-names>J.</given-names></name>
<name><surname>Kuo</surname><given-names>A.</given-names></name>
<name><surname>Schiano</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study</article-title><source>Gastroenterology</source><year>2015</year><volume>148</volume><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.09.023</pub-id><pub-id pub-id-type="pmid">25261839</pub-id>
</element-citation></ref><ref id="B83-viruses-17-00163"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gane</surname><given-names>E.J.</given-names></name>
<name><surname>Agarwal</surname><given-names>K.</given-names></name>
</person-group><article-title>Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: &#x0201c;A flood of opportunity&#x0201d;</article-title><source>Am. J. Transplant.</source><year>2014</year><volume>14</volume><fpage>994</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1111/ajt.12714</pub-id><pub-id pub-id-type="pmid">24730431</pub-id>
</element-citation></ref><ref id="B84-viruses-17-00163"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Charlton</surname><given-names>M.</given-names></name>
<name><surname>Gane</surname><given-names>E.</given-names></name>
<name><surname>Manns</surname><given-names>M.P.</given-names></name>
<name><surname>Brown</surname><given-names>R.S.</given-names></name>
<name><surname>Curry</surname><given-names>M.P.</given-names></name>
<name><surname>Kwo</surname><given-names>P.Y.</given-names></name>
<name><surname>Fontana</surname><given-names>R.J.</given-names></name>
<name><surname>Gilroy</surname><given-names>R.</given-names></name>
<name><surname>Teperman</surname><given-names>L.</given-names></name>
<name><surname>Muir</surname><given-names>A.J.</given-names></name>
<etal/>
</person-group><article-title>Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation</article-title><source>Gastroenterology</source><year>2015</year><volume>148</volume><fpage>108</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.10.001</pub-id><pub-id pub-id-type="pmid">25304641</pub-id>
</element-citation></ref><ref id="B85-viruses-17-00163"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Afdhal</surname><given-names>N.</given-names></name>
<name><surname>Zeuzem</surname><given-names>S.</given-names></name>
<name><surname>Kwo</surname><given-names>P.</given-names></name>
<name><surname>Chojkier</surname><given-names>M.</given-names></name>
<name><surname>Gitlin</surname><given-names>N.</given-names></name>
<name><surname>Puoti</surname><given-names>M.</given-names></name>
<name><surname>Romero-Gomez</surname><given-names>M.</given-names></name>
<name><surname>Zarski</surname><given-names>J.-P.</given-names></name>
<name><surname>Agarwal</surname><given-names>K.</given-names></name>
<name><surname>Buggisch</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>370</volume><fpage>1889</fpage><lpage>1898</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1402454</pub-id><pub-id pub-id-type="pmid">24725239</pub-id>
</element-citation></ref><ref id="B86-viruses-17-00163"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Afdhal</surname><given-names>N.</given-names></name>
<name><surname>Reddy</surname><given-names>K.R.</given-names></name>
<name><surname>Nelson</surname><given-names>D.R.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Schiff</surname><given-names>E.</given-names></name>
<name><surname>Nahass</surname><given-names>R.</given-names></name>
<name><surname>Ghalib</surname><given-names>R.</given-names></name>
<name><surname>Gitlin</surname><given-names>N.</given-names></name>
<name><surname>Herring</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>370</volume><fpage>1483</fpage><lpage>1493</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1316366</pub-id><pub-id pub-id-type="pmid">24725238</pub-id>
</element-citation></ref><ref id="B87-viruses-17-00163"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Poordad</surname><given-names>F.F.</given-names></name>
<name><surname>Pang</surname><given-names>P.S.</given-names></name>
<name><surname>Hyland</surname><given-names>R.H.</given-names></name>
<name><surname>Ding</surname><given-names>X.</given-names></name>
<name><surname>Mo</surname><given-names>H.</given-names></name>
<name><surname>Symonds</surname><given-names>W.T.</given-names></name>
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
<name><surname>Membreno</surname><given-names>F.E.</given-names></name>
</person-group><article-title>Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial</article-title><source>Lancet</source><year>2014</year><volume>383</volume><fpage>515</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)62121-2</pub-id><pub-id pub-id-type="pmid">24209977</pub-id>
</element-citation></ref><ref id="B88-viruses-17-00163"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kowdley</surname><given-names>K.V.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Reddy</surname><given-names>K.R.</given-names></name>
<name><surname>Rossaro</surname><given-names>L.</given-names></name>
<name><surname>Bernstein</surname><given-names>D.E.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.L.</given-names></name>
<name><surname>Schiff</surname><given-names>E.</given-names></name>
<name><surname>Ghalib</surname><given-names>R.</given-names></name>
<name><surname>Ryan</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>370</volume><fpage>1879</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1402355</pub-id><pub-id pub-id-type="pmid">24720702</pub-id>
</element-citation></ref><ref id="B89-viruses-17-00163"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poordad</surname><given-names>F.</given-names></name>
<name><surname>Sievert</surname><given-names>W.</given-names></name>
<name><surname>Mollison</surname><given-names>L.</given-names></name>
<name><surname>Bennett</surname><given-names>M.</given-names></name>
<name><surname>Tse</surname><given-names>E.</given-names></name>
<name><surname>Br&#x000e4;u</surname><given-names>N.</given-names></name>
<name><surname>Levin</surname><given-names>J.</given-names></name>
<name><surname>Sepe</surname><given-names>T.</given-names></name>
<name><surname>Lee</surname><given-names>S.S.</given-names></name>
<name><surname>Angus</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patientswith HCV genotype 1 infection</article-title><source>JAMA</source><year>2015</year><volume>313</volume><fpage>1728</fpage><lpage>1735</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.3860</pub-id><pub-id pub-id-type="pmid">25942723</pub-id>
</element-citation></ref><ref id="B90-viruses-17-00163"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muir</surname><given-names>A.J.</given-names></name>
<name><surname>Poordad</surname><given-names>F.</given-names></name>
<name><surname>Lalezari</surname><given-names>J.</given-names></name>
<name><surname>Everson</surname><given-names>G.</given-names></name>
<name><surname>Dore</surname><given-names>G.J.</given-names></name>
<name><surname>Herring</surname><given-names>R.</given-names></name>
<name><surname>Sheikh</surname><given-names>A.</given-names></name>
<name><surname>Kwo</surname><given-names>P.</given-names></name>
<name><surname>H&#x000e9;zode</surname><given-names>C.</given-names></name>
<name><surname>Pockros</surname><given-names>P.J.</given-names></name>
<etal/>
</person-group><article-title>Daclatasvir in combination with asunaprevir and beclabuvirfor hepatitis C virus genotype 1 infection with compensated cirrhosis</article-title><source>JAMA</source><year>2015</year><volume>313</volume><fpage>1736</fpage><lpage>1744</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.3868</pub-id><pub-id pub-id-type="pmid">25942724</pub-id>
</element-citation></ref><ref id="B91-viruses-17-00163"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naggie</surname><given-names>S.</given-names></name>
<name><surname>Cooper</surname><given-names>C.</given-names></name>
<name><surname>Saag</surname><given-names>M.</given-names></name>
<name><surname>Workowski</surname><given-names>K.</given-names></name>
<name><surname>Ruane</surname><given-names>P.</given-names></name>
<name><surname>Towner</surname><given-names>W.J.</given-names></name>
<name><surname>Marks</surname><given-names>K.</given-names></name>
<name><surname>Luetkemeyer</surname><given-names>A.</given-names></name>
<name><surname>Baden</surname><given-names>R.P.</given-names></name>
<name><surname>Sax</surname><given-names>P.E.</given-names></name>
<etal/>
</person-group><article-title>Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>705</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1501315</pub-id><pub-id pub-id-type="pmid">26196665</pub-id>
</element-citation></ref><ref id="B92-viruses-17-00163"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liao</surname><given-names>H.T.</given-names></name>
<name><surname>Tan</surname><given-names>P.</given-names></name>
<name><surname>Huang</surname><given-names>J.W.</given-names></name>
<name><surname>Yuan</surname><given-names>K.F.</given-names></name>
</person-group><article-title>Ledipasvir + Sofosbuvir for Liver Transplant Recipients with Recurrent Hepatitis C: A Systematic Review and Meta-Analysis</article-title><source>Transplant. Proc.</source><year>2017</year><volume>49</volume><fpage>1855</fpage><lpage>1863</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2017.04.014</pub-id><pub-id pub-id-type="pmid">28923637</pub-id>
</element-citation></ref><ref id="B93-viruses-17-00163"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cotter</surname><given-names>T.G.</given-names></name>
<name><surname>Jensen</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: Design, development, and place in therapy</article-title><source>Drug Des. Dev. Ther.</source><year>2019</year><volume>13</volume><fpage>2565</fpage><lpage>2577</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S172512</pub-id><pub-id pub-id-type="pmid">31534310</pub-id>
</element-citation></ref><ref id="B94-viruses-17-00163"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hubbard</surname><given-names>H.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
</person-group><article-title>Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C</article-title><source>Expert Rev. Gastroenterol. Hepatol.</source><year>2018</year><volume>12</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1080/17474124.2018.1411802</pub-id><pub-id pub-id-type="pmid">29187007</pub-id>
</element-citation></ref><ref id="B95-viruses-17-00163"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jackson</surname><given-names>W.E.</given-names></name>
<name><surname>Everson</surname><given-names>G.T.</given-names></name>
</person-group><article-title>Sofosbuvir and velpatasvir for the treatment of hepatitis C</article-title><source>Expert Rev. Gastroenterol. Hepatol.</source><year>2017</year><volume>11</volume><fpage>501</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1080/17474124.2017.1326817</pub-id><pub-id pub-id-type="pmid">28468532</pub-id>
</element-citation></ref><ref id="B96-viruses-17-00163"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chahine</surname><given-names>E.B.</given-names></name>
<name><surname>Sucher</surname><given-names>A.J.</given-names></name>
<name><surname>Hemstreet</surname><given-names>B.A.</given-names></name>
</person-group><article-title>Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C</article-title><source>Ann. Pharmacother.</source><year>2017</year><volume>51</volume><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1177/1060028016668897</pub-id><pub-id pub-id-type="pmid">27609942</pub-id>
</element-citation></ref><ref id="B97-viruses-17-00163"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>R.</given-names></name>
<name><surname>Kottilil</surname><given-names>S.</given-names></name>
<name><surname>Wilson</surname><given-names>E.</given-names></name>
</person-group><article-title>Sofosbuvir/velpatasvir: A pangenotypic drug to simplify HCV therapy</article-title><source>Hepatol. Int.</source><year>2017</year><volume>11</volume><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1007/s12072-016-9776-8</pub-id><pub-id pub-id-type="pmid">27928718</pub-id>
</element-citation></ref><ref id="B98-viruses-17-00163"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toyoda</surname><given-names>H.</given-names></name>
</person-group><article-title>Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: How should we choose among these two latest and probably the last regimens?</article-title><source>Hepatol. Res.</source><year>2022</year><volume>52</volume><fpage>815</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1111/hepr.13828</pub-id><pub-id pub-id-type="pmid">36181692</pub-id>
</element-citation></ref><ref id="B99-viruses-17-00163"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feld</surname><given-names>J.J.</given-names></name>
<name><surname>Jacobson</surname><given-names>I.M.</given-names></name>
<name><surname>H&#x000e9;zode</surname><given-names>C.</given-names></name>
<name><surname>Asselah</surname><given-names>T.</given-names></name>
<name><surname>Ruane</surname><given-names>P.J.</given-names></name>
<name><surname>Gruener</surname><given-names>N.</given-names></name>
<name><surname>Abergel</surname><given-names>A.</given-names></name>
<name><surname>Mangia</surname><given-names>A.</given-names></name>
<name><surname>Lai</surname><given-names>C.-L.</given-names></name>
<name><surname>Chan</surname><given-names>H.L.Y.</given-names></name>
<etal/>
</person-group><article-title>Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>2599</fpage><lpage>2607</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1512610</pub-id><pub-id pub-id-type="pmid">26571066</pub-id>
</element-citation></ref><ref id="B100-viruses-17-00163"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foster</surname><given-names>G.R.</given-names></name>
<name><surname>Afdhal</surname><given-names>N.</given-names></name>
<name><surname>Roberts</surname><given-names>S.K.</given-names></name>
<name><surname>Br&#x000e4;u</surname><given-names>N.</given-names></name>
<name><surname>Gane</surname><given-names>E.J.</given-names></name>
<name><surname>Pianko</surname><given-names>S.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Thompson</surname><given-names>A.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.L.</given-names></name>
<name><surname>Cooper</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>2608</fpage><lpage>2617</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1512612</pub-id><pub-id pub-id-type="pmid">26575258</pub-id>
</element-citation></ref><ref id="B101-viruses-17-00163"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Curry</surname><given-names>M.P.</given-names></name>
<name><surname>O&#x02019;Leary</surname><given-names>J.G.</given-names></name>
<name><surname>Bzowej</surname><given-names>N.</given-names></name>
<name><surname>Muir</surname><given-names>A.J.</given-names></name>
<name><surname>Korenblat</surname><given-names>K.M.</given-names></name>
<name><surname>Fenkel</surname><given-names>J.M.</given-names></name>
<name><surname>Reddy</surname><given-names>K.R.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Flamm</surname><given-names>S.L.</given-names></name>
<name><surname>Schiano</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>2618</fpage><lpage>2628</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1512614</pub-id><pub-id pub-id-type="pmid">26569658</pub-id>
</element-citation></ref><ref id="B102-viruses-17-00163"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Forns</surname><given-names>X.</given-names></name>
<name><surname>Lee</surname><given-names>S.S.</given-names></name>
<name><surname>Valdes</surname><given-names>J.</given-names></name>
<name><surname>Lens</surname><given-names>S.</given-names></name>
<name><surname>Ghalib</surname><given-names>R.</given-names></name>
<name><surname>Aguilar</surname><given-names>H.</given-names></name>
<name><surname>Felizarta</surname><given-names>F.</given-names></name>
<name><surname>Hassanein</surname><given-names>T.</given-names></name>
<name><surname>Hinrichsen</surname><given-names>H.</given-names></name>
<name><surname>Rincon</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial</article-title><source>Lancet Infect. Dis.</source><year>2017</year><volume>17</volume><fpage>1062</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30496-6</pub-id><pub-id pub-id-type="pmid">28818546</pub-id>
</element-citation></ref><ref id="B103-viruses-17-00163"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeuzem</surname><given-names>S.</given-names></name>
<name><surname>Foster</surname><given-names>G.R.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Asatryan</surname><given-names>A.</given-names></name>
<name><surname>Gane</surname><given-names>E.</given-names></name>
<name><surname>Feld</surname><given-names>J.J.</given-names></name>
<name><surname>Asselah</surname><given-names>T.</given-names></name>
<name><surname>Bourli&#x000e8;re</surname><given-names>M.</given-names></name>
<name><surname>Ruane</surname><given-names>P.J.</given-names></name>
<name><surname>Wedemeyer</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>354</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1702417</pub-id><pub-id pub-id-type="pmid">29365309</pub-id>
</element-citation></ref><ref id="B104-viruses-17-00163"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bourli&#x000e8;re</surname><given-names>M.</given-names></name>
<name><surname>Gordon</surname><given-names>S.C.</given-names></name>
<name><surname>Flamm</surname><given-names>S.L.</given-names></name>
<name><surname>Cooper</surname><given-names>C.L.</given-names></name>
<name><surname>Ramji</surname><given-names>A.</given-names></name>
<name><surname>Tong</surname><given-names>M.</given-names></name>
<name><surname>Ravendhran</surname><given-names>N.</given-names></name>
<name><surname>Vierling</surname><given-names>J.M.</given-names></name>
<name><surname>Tran</surname><given-names>T.T.</given-names></name>
<name><surname>Pianko</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>37</volume><fpage>2134</fpage><lpage>2146</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1613512</pub-id><pub-id pub-id-type="pmid">28564569</pub-id>
</element-citation></ref><ref id="B105-viruses-17-00163"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feld</surname><given-names>J.J.</given-names></name>
<name><surname>Forns</surname><given-names>X.</given-names></name>
<name><surname>Dylla</surname><given-names>D.E.</given-names></name>
<name><surname>Kumada</surname><given-names>H.</given-names></name>
<name><surname>de Ledinghen</surname><given-names>V.</given-names></name>
<name><surname>Wei</surname><given-names>L.</given-names></name>
<name><surname>Brown</surname><given-names>R.S.</given-names></name>
<name><surname>Flisiak</surname><given-names>R.</given-names></name>
<name><surname>Lampertico</surname><given-names>P.</given-names></name>
<name><surname>Thabut</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts</article-title><source>J. Viral Hepat.</source><year>2022</year><volume>29</volume><fpage>1050</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1111/jvh.13738</pub-id><pub-id pub-id-type="pmid">36036117</pub-id>
</element-citation></ref><ref id="B106-viruses-17-00163"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Forns</surname><given-names>X.</given-names></name>
<name><surname>Feld</surname><given-names>J.J.</given-names></name>
<name><surname>Dylla</surname><given-names>D.E.</given-names></name>
<name><surname>Pol</surname><given-names>S.</given-names></name>
<name><surname>Chayama</surname><given-names>K.</given-names></name>
<name><surname>Hou</surname><given-names>J.</given-names></name>
<name><surname>Heo</surname><given-names>J.</given-names></name>
<name><surname>Lampertico</surname><given-names>P.</given-names></name>
<name><surname>Brown</surname><given-names>A.</given-names></name>
<name><surname>Bondin</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts</article-title><source>Adv. Ther.</source><year>2021</year><volume>38</volume><fpage>3409</fpage><lpage>3426</lpage><pub-id pub-id-type="doi">10.1007/s12325-021-01753-3</pub-id><pub-id pub-id-type="pmid">34021887</pub-id>
</element-citation></ref><ref id="B107-viruses-17-00163"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takehara</surname><given-names>T.</given-names></name>
<name><surname>Izumi</surname><given-names>N.</given-names></name>
<name><surname>Mochida</surname><given-names>S.</given-names></name>
<name><surname>Genda</surname><given-names>T.</given-names></name>
<name><surname>Fujiyama</surname><given-names>S.</given-names></name>
<name><surname>Notsumata</surname><given-names>K.</given-names></name>
<name><surname>Tamori</surname><given-names>A.</given-names></name>
<name><surname>Suzuki</surname><given-names>F.</given-names></name>
<name><surname>Suri</surname><given-names>V.</given-names></name>
<name><surname>Mercier</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan</article-title><source>Hepatol. Res.</source><year>2022</year><volume>52</volume><fpage>833</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1111/hepr.13810</pub-id><pub-id pub-id-type="pmid">35802063</pub-id>
</element-citation></ref><ref id="B108-viruses-17-00163"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flamm</surname><given-names>S.</given-names></name>
<name><surname>Lawitz</surname><given-names>E.</given-names></name>
<name><surname>Borg</surname><given-names>B.</given-names></name>
<name><surname>Charlton</surname><given-names>M.</given-names></name>
<name><surname>Landis</surname><given-names>C.</given-names></name>
<name><surname>Reddy</surname><given-names>K.R.</given-names></name>
<name><surname>Shiffman</surname><given-names>M.</given-names></name>
<name><surname>Alsina</surname><given-names>A.</given-names></name>
<name><surname>Chang</surname><given-names>C.</given-names></name>
<name><surname>Ravendhran</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>2026</elocation-id><pub-id pub-id-type="doi">10.3390/v15102026</pub-id><pub-id pub-id-type="pmid">37896803</pub-id>
</element-citation></ref><ref id="B109-viruses-17-00163"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Llaneras</surname><given-names>J.</given-names></name>
<name><surname>Riveiro-Barciela</surname><given-names>M.</given-names></name>
<name><surname>Lens</surname><given-names>S.</given-names></name>
<name><surname>Diago</surname><given-names>M.</given-names></name>
<name><surname>Cachero</surname><given-names>A.</given-names></name>
<name><surname>Garc&#x000ed;a-Samaniego</surname><given-names>J.</given-names></name>
<name><surname>Conde</surname><given-names>I.</given-names></name>
<name><surname>Arencibia</surname><given-names>A.</given-names></name>
<name><surname>Arenas</surname><given-names>J.</given-names></name>
<name><surname>Gea</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs</article-title><source>J. Hepatol.</source><year>2019</year><volume>71</volume><fpage>666</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.06.002</pub-id><pub-id pub-id-type="pmid">31203153</pub-id>
</element-citation></ref><ref id="B110-viruses-17-00163"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruiz-Cobo</surname><given-names>J.C.</given-names></name>
<name><surname>Llaneras</surname><given-names>J.</given-names></name>
<name><surname>Forns</surname><given-names>X.</given-names></name>
<name><surname>Moya</surname><given-names>A.G.</given-names></name>
<name><surname>Amiel</surname><given-names>I.C.</given-names></name>
<name><surname>Arencibia</surname><given-names>A.</given-names></name>
<name><surname>Diago</surname><given-names>M.</given-names></name>
<name><surname>Garc&#x000ed;a-Samaniego</surname><given-names>J.</given-names></name>
<name><surname>Castellote</surname><given-names>J.</given-names></name>
<name><surname>Llerena</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir</article-title><source>Aliment. Pharmacol. Ther.</source><year>2024</year><volume>60</volume><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1111/apt.18020</pub-id><pub-id pub-id-type="pmid">38695095</pub-id>
</element-citation></ref><ref id="B111-viruses-17-00163"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reiberger</surname><given-names>T.</given-names></name>
<name><surname>Lens</surname><given-names>S.</given-names></name>
<name><surname>Cabibbo</surname><given-names>G.</given-names></name>
<name><surname>Nahon</surname><given-names>P.</given-names></name>
<name><surname>Zignego</surname><given-names>A.L.</given-names></name>
<name><surname>Deterding</surname><given-names>K.</given-names></name>
<name><surname>Elsharkawy</surname><given-names>A.M.</given-names></name>
<name><surname>Forns</surname><given-names>X.</given-names></name>
</person-group><article-title>EASL position paper on clinical follow-up after HCV cure</article-title><source>J. Hepatol.</source><year>2024</year><volume>81</volume><fpage>326</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2024.04.007</pub-id><pub-id pub-id-type="pmid">38845253</pub-id>
</element-citation></ref><ref id="B112-viruses-17-00163"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harney</surname><given-names>B.L.</given-names></name>
<name><surname>Sacks-Davis</surname><given-names>R.</given-names></name>
<name><surname>van Santen</surname><given-names>D.K.</given-names></name>
<name><surname>Traeger</surname><given-names>M.W.</given-names></name>
<name><surname>Wilkinson</surname><given-names>A.L.</given-names></name>
<name><surname>Asselin</surname><given-names>J.</given-names></name>
<name><surname>Fairley</surname><given-names>C.K.</given-names></name>
<name><surname>Roth</surname><given-names>N.</given-names></name>
<name><surname>Bloch</surname><given-names>M.</given-names></name>
<name><surname>Matthews</surname><given-names>G.V.</given-names></name>
<etal/>
</person-group><article-title>Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020</article-title><source>Liver Int.</source><year>2024</year><volume>44</volume><fpage>1024</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1111/liv.15841</pub-id><pub-id pub-id-type="pmid">38291946</pub-id>
</element-citation></ref><ref id="B113-viruses-17-00163"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Young</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Lani&#x000e8;ce Delaunay</surname><given-names>C.</given-names></name>
<name><surname>Cooper</surname><given-names>C.L.</given-names></name>
<name><surname>Cox</surname><given-names>J.</given-names></name>
<name><surname>Gill</surname><given-names>M.J.</given-names></name>
<name><surname>Hull</surname><given-names>M.</given-names></name>
<name><surname>Walmsley</surname><given-names>S.</given-names></name>
<name><surname>Wong</surname><given-names>A.</given-names></name>
<name><surname>Klein</surname><given-names>M.B.</given-names></name>
</person-group><article-title>The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination</article-title><source>Int. J. Drug Policy</source><year>2023</year><volume>114</volume><fpage>103981</fpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2023.103981</pub-id><pub-id pub-id-type="pmid">36893502</pub-id>
</element-citation></ref><ref id="B114-viruses-17-00163"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karasz</surname><given-names>A.</given-names></name>
<name><surname>Merchant</surname><given-names>K.</given-names></name>
<name><surname>Singh</surname><given-names>R.</given-names></name>
<name><surname>Thomas</surname><given-names>A.</given-names></name>
<name><surname>Borsuk</surname><given-names>C.</given-names></name>
<name><surname>McKee</surname><given-names>D.</given-names></name>
<name><surname>Duryea</surname><given-names>P.</given-names></name>
<name><surname>Kim</surname><given-names>A.Y.</given-names></name>
<name><surname>Mehta</surname><given-names>S.</given-names></name>
<name><surname>Norton</surname><given-names>B.L.</given-names></name>
<etal/>
</person-group><article-title>The experience of re-infection among people who inject drugs successfully treated for hepatitis C</article-title><source>J. Subst. Use Addict. Treat.</source><year>2023</year><volume>146</volume><fpage>208937</fpage><pub-id pub-id-type="doi">10.1016/j.josat.2022.208937</pub-id><pub-id pub-id-type="pmid">36880897</pub-id>
</element-citation></ref><ref id="B115-viruses-17-00163"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>F.</given-names></name>
<name><surname>Blach</surname><given-names>S.</given-names></name>
<name><surname>Manzengo Mingiedi</surname><given-names>C.</given-names></name>
<name><surname>Gonzalez</surname><given-names>M.A.</given-names></name>
<name><surname>Alaama</surname><given-names>A.S.</given-names></name>
<name><surname>Mozalevskis</surname><given-names>A.</given-names></name>
<name><surname>S&#x000e9;guy</surname><given-names>N.</given-names></name>
<name><surname>Rewari</surname><given-names>B.B.</given-names></name>
<name><surname>Chan</surname><given-names>P.-L.</given-names></name>
<name><surname>Le</surname><given-names>L.-V.</given-names></name>
<etal/>
</person-group><article-title>Global reporting of progress towards elimination of hepatitis B and hepatitis C</article-title><source>Lancet Gastroenterol. Hepatol.</source><year>2023</year><volume>8</volume><fpage>332</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(22)00386-7</pub-id><pub-id pub-id-type="pmid">36764320</pub-id>
</element-citation></ref><ref id="B116-viruses-17-00163"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Razavi</surname><given-names>H.</given-names></name>
</person-group><article-title>Polaris Observatory-supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis</article-title><source>Antivir. Ther.</source><year>2022</year><volume>27</volume><fpage>13596535221083179</fpage><pub-id pub-id-type="doi">10.1177/13596535221083179</pub-id><pub-id pub-id-type="pmid">35499176</pub-id>
</element-citation></ref><ref id="B117-viruses-17-00163"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tu</surname><given-names>S.S.</given-names></name>
<name><surname>Kottilil</surname><given-names>S.</given-names></name>
<name><surname>Mattingly</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Leveraging Old Hepatitis C Therapies</article-title><source>N. Engl. J. Med.</source><year>2025</year><volume>392</volume><fpage>2</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1056/NEJMp2409842</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="viruses-17-00163-t001"><object-id pub-id-type="pii">viruses-17-00163-t001_Table 1</object-id><label>Table 1</label><caption><p>Interferon-based therapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Authors </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genotypes</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment Regimens</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Weeks of Therapy</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Patients</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SVR (%) </th></tr></thead><tbody><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
McHutchison et al.
</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B33-viruses-17-00163" ref-type="bibr">33</xref>]</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1998</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1,2,3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2b 3 MU tiw</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">231</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2b 3 MU tiw</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">225</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2b 3 MU tiw plus RBV 1000&#x02013;1200 mg/day</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">228</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2b 3 MU tiw plus RBV 1000&#x02013;1200 mg/day</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">228</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Poynard</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B34-viruses-17-00163" ref-type="bibr">34</xref>]</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1998</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1,2,3,4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2b 3 MU tiw plus RBV 1000&#x02013;1200 mg/day </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
277
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2b 3 MU tiw plus RBV 1000&#x02013;1200 mg/day</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">277</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2b 3 MU tiw plus Placebo </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
278
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Lindsay et al.</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B35-viruses-17-00163" ref-type="bibr">35</xref>]</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2001</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1,2,3,4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2b 0.5 &#x003bc;g/kg </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">315</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2b 1.0 &#x003bc;g/kg</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">297</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2b 1.5 &#x003bc;g/kg </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">304</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2b 3 MU tiw</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">303</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Zeuzem et al.</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B36-viruses-17-00163" ref-type="bibr">36</xref>]</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2000</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1,2,3,4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2a 180 &#x003bc;g</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">267</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2a 6 and then 3 MU tiw </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">264</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Heathcote et al.<break/>All patients stage 3/4 </td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B37-viruses-17-00163" ref-type="bibr">37</xref>]</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2000</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1,2,3,4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2a 90 &#x003bc;g </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2a 180 &#x003bc;g</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2a 3 MU tiw</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Manns et al.</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B38-viruses-17-00163" ref-type="bibr">38</xref>]</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2001</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1,2,3,4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2b 1.5 &#x003bc;g/kg plus RBV 800 mg/day</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">511</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2b 1.5 &#x003bc;g/kg for 4 weeks then 0.5 &#x003bc;g/kg for 44 weeks plus RBV 1000&#x02013;1200 mg/day</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">514</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2b 3 MU tiw plus RBV 1000&#x02013;1200 mg/day</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">505</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Fried et al.</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B39-viruses-17-00163" ref-type="bibr">39</xref>]</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2002</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1,2,3,4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2a 180 &#x003bc;g plus RBV 1000&#x02013;1200 mg/day</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">453</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2a 180 &#x003bc;g</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">224</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN &#x003b1;-2b 3 MU tiw plus RBV 1000&#x02013;1200 mg/day</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">444</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Kamal et al. </td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B40-viruses-17-00163" ref-type="bibr">40</xref>]</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2007</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2b 1.5 &#x003bc;g/kg plus RBV (10.6 mg/kg/day)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2b 1.5 &#x003bc;g/kg plus RBV (10.6 mg/kg/day)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2b 1.5 &#x003bc;g/kg plus RBV (10.6 mg/kg/day)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2b 1.5 &#x003bc;g/kg plus RBV (10.6 mg/kg/day)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">160</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
McHutchison et al.
</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B41-viruses-17-00163" ref-type="bibr">41</xref>]</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2009</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2b 1.5 &#x003bc;g/kg plus RBV 800&#x02013;1400 mg/day</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1019</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2b 1.0 &#x003bc;g/kg plus RBV 800&#x02013;1400 mg/day</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1015</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-IFN &#x003b1;-2a 180 &#x003bc;g plus RBV 800&#x02013;1400 mg/day</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1035</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: MU = mega units, tiw = three times a week.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-00163-t002"><object-id pub-id-type="pii">viruses-17-00163-t002_Table 2</object-id><label>Table 2</label><caption><p>Therapy with first-generation direct-acting antivirals (DAAs).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Authors </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genotypes</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virological Status</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment Regimens</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Weeks of Therapy</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Patients</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SVR (%) </th></tr></thead><tbody><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">McHutchison GJ et al. </td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B50-viruses-17-00163" ref-type="bibr">50</xref>]</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2009</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Placebo for 12 weeks plus peginterferon alfa-2a and ribavirin for 48 weeks</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">telaprevir, peginterferon alfa-2a and ribavirin for 12 weeks </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">telaprevir for 12 weeks plus peginterferon alfa-2a and ribavirin for 24 weeks</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">telaprevir for 12 weeks plus peginterferon alfa-2a and ribavirin for 48 weeks. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">H&#x000e9;zode C et al. </td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B51-viruses-17-00163" ref-type="bibr">51</xref>]</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">telaprevir, peginterferon alfa-2a and ribavirin for 12 weeks, followed by peginterferon alfa-2a and ribavirin for 12 more weeks. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">telaprevir, peginterferon alfa-2a and ribavirin for 12 weeks,</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">telaprevir and peginterferon alfa-2a for 12 weeks,</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2a and ribavirin for 48 weeks.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">McHutchison JG et al. </td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B52-viruses-17-00163" ref-type="bibr">52</xref>]</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">previously treated</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">telaprevir for 12 weeks plus peginterferon alfa-2a and ribavirin for 24 weeks; </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">115</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">telaprevir for 24 weeks plus peginterferon alfa-2a and ribavirin for 48 weeks</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">telaprevir for 24 weeks plus peginterferon alfa-2a and ribavirin for 24 weeks</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2a and ribavirin for 48 weeks </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">114</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Jacobson IM et al. </td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B53-viruses-17-00163" ref-type="bibr">53</xref>]</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">telaprevir combined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR group), followed by peginterferon-ribavirin alone for 12 weeks if HCV RNA was undetectable at weeks 4 and 12 or for 36 weeks if HCV RNA was detectable at either time point;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24&#x02013;36</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">363</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">telaprevir with peginterferon-ribavirin for 8 weeks and placebo with peginterferon-ribavirin for 4 weeks (T8PR group), followed by 12 or 36 weeks of peginterferon-ribavirin on the basis of the same HCV RNA criteria; </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36&#x02013;48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">364</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">placebo with peginterferon-ribavirin for 12 weeks, followed by 36 weeks of peginterferon-ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">361</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Zeuzem S et al. </td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B54-viruses-17-00163" ref-type="bibr">54</xref>]</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">previously treated</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">the T12PR48 group, received telaprevir for 12 weeks and peginterferon plus ribavirin for a total of 48 weeks;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">266</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T12PR48 group, received 4 weeks of peginterferon plus ribavirin followed by 12 weeks of telaprevir and peginterferon plus ribavirin for a total of 48 weeks; </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">264</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon plus ribavirin for 48 weeks. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td></tr><tr><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Kwo PY et al. </td><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B55-viruses-17-00163" ref-type="bibr">55</xref>]</td><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2b plus ribavirin for 48 weeks </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">104</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2b plus ribavirin for 4 weeks, followed by peginterferon alfa-2b, ribavirin, and boceprevir for 24 weeks</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2b plus ribavirin for 4 weeks followed by peginterferon alfa-2b, ribavirin, and boceprevir for 44 weeks </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2b plus ribavirin and boceprevir for 28 weeks </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2b plus ribavirin and boceprevir for 48 weeks. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Poordad F et al. </td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B56-viruses-17-00163" ref-type="bibr">56</xref>]</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2b and ribavirin were administered for 4 weeks (the lead-in period) and subsequently, placebo plus peginterferon-ribavirin for 44 weeks;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">363</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2b and ribavirin were administered for 4 weeks (the lead-in period) and subsequently boceprevir plus peginterferon-ribavirin for 24 weeks, and those with a detectable HCV RNA level between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an additional 20 weeks</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">368</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2b and ribavirin for 4 weeks (the lead-in period) and subsequently boceprevir plus peginterferon-ribavirin for 44 weeks.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">366</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Bacon BR et al. </td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B57-viruses-17-00163" ref-type="bibr">57</xref>]</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">previously treated</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2b and ribavirin for 4 weeks (the lead-in period) and subsequently placebo plus peginterferon-ribavirin for 44 weeks;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2b and ribavirin for 4 weeks (the lead-in period) and subsequently boceprevir plus peginterferon-ribavirin for 32 weeks, and patients with a detectable HCV RNA level at week 8 received placebo plus peginterferon-ribavirin for an additional 12 weeks; </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">162</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peginterferon alfa-2b and ribavirin were administered for 4 weeks (the lead-in period) and subsequently received boceprevir plus peginterferon-ribavirin for 44 weeks.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">161</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00163-t003"><object-id pub-id-type="pii">viruses-17-00163-t003_Table 3</object-id><label>Table 3</label><caption><p>DAAs of the second and third generation with the protein inhibited, typical combination and year of approval.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">DAA</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Protein Inhibited</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Typical Combination</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year of Approval</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sofosbuvir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS5B (polymerase)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir + Ledipasvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Ledipasvir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS5A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir + Ledipasvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Ombitasvir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS5A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ombitasvir + Paritaprevir + Dasabuvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Paritaprevir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS3/4A (protease)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ombitasvir + Paritaprevir + Dasabuvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Dasabuvir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS5B (non-nucleoside)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ombitasvir + Paritaprevir + Dasabuvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Asunaprevir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS3/4A (protease)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beclabuvir + Daclatasvir + Asunaprevir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Daclatasvir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS5A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir + Daclatasvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Beclabuvir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS5B (non-nucleoside)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beclabuvir + Daclatasvir + Asunaprevir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Velpatasvir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS5A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir + Velpatasvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Elbasvir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS5A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Grazoprevir + Elbasvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Grazoprevir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS3/4A (protease)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Grazoprevir + Elbasvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Glecaprevir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS3/4A (protease)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glecaprevir + Pibrentasvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Pibrentasvir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS5A</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glecaprevir + Pibrentasvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Voxilaprevir</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NS3/4A (protease)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir + Velpatasvir + Voxilaprevir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00163-t004"><object-id pub-id-type="pii">viruses-17-00163-t004_Table 4</object-id><label>Table 4</label><caption><p>Therapy with second-generation direct-acting antivirals (DAAs).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Authors </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genotypes</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virological Status</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment Regimens</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Weeks of Therapy</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Patients</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SVR <break/>(%) </th></tr></thead><tbody><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Afdhal N et al. </td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B84-viruses-17-00163" ref-type="bibr">84</xref>]</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2014</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">214</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir plus ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">217</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">217</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir plus ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">217</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Afdhal N et al. </td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B85-viruses-17-00163" ref-type="bibr">85</xref>]</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2014</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">previously treated</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir plus ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir plus ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td></tr><tr><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Lawitz E et al.</td><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B86-viruses-17-00163" ref-type="bibr">86</xref>]</td><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2014</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated (Cohort A)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir plus ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">previously treated with a protease-inhibitor regimen (Cohort B)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir plus ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Kowdley KV et al. </td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B87-viruses-17-00163" ref-type="bibr">87</xref>]</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2014</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">215</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir plus ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">216</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sofosbuvir-ledipasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">215</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Poordard F et al.</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B88-viruses-17-00163" ref-type="bibr">88</xref>]</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2015</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">untreated</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">daclatasvir&#x02014;asunaprevir beclabuvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">312</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">previously treated</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">daclatasvir&#x02014;asunaprevir-beclabuvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Muir AJ et al. </td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B89-viruses-17-00163" ref-type="bibr">89</xref>]</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2015</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated cirrhosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">daclatasvir&#x02014;asunaprevir-beclabuvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">daclatasvir&#x02014;asunaprevir-beclabuvir plus ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">previously treated cirrhosis </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">daclatasvir&#x02014;asunaprevir-beclabuvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">daclatasvir&#x02014;asunaprevir-beclabuvir plus ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-17-00163-t005"><object-id pub-id-type="pii">viruses-17-00163-t005_Table 5</object-id><label>Table 5</label><caption><p>Therapy with pan-genotypic direct-acting antivirals (DAAs).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Authors </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genotypes</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virological Status</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment Regimens</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Weeks of Therapy</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Patients</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SVR <break/>(%) </th></tr></thead><tbody><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Feld JJ et al. </td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B99-viruses-17-00163" ref-type="bibr">99</xref>]</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2015</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1,2,4,5,6 </td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated (68%)<break/>previously treated (32%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir&#x02013;Velpatasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">624</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Placebo</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">116</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Foster GR et al. </td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B100-viruses-17-00163" ref-type="bibr">100</xref>]</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2015</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated <break/>previously treated </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir&#x02013;Velpatasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">134</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir&#x02013;Ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">3</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated <break/>previously treated </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir&#x02013;Velpatasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">277</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir&#x02013;Ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">275</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Curry MP et al. </td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B101-viruses-17-00163" ref-type="bibr">101</xref>]</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">2015</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1,2,3,4,5,6</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated and previously treated decompensated cirrhosis </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir&#x02013;Velpatasvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir&#x02013;Velpatasvir plus Ribavirin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir&#x02013;Velpatasvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Forns X et al.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-viruses-17-00163" ref-type="bibr">102</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,2,4,5,6</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">untreated and previously treated compensated cirrhosis </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glecaprevir-Pibrentasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">146</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td></tr><tr><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Zeuzem S et al.</td><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B103-viruses-17-00163" ref-type="bibr">103</xref>]</td><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated <break/>previously treated</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glecaprevir-Pibrentasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">351</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glecaprevir-Pibrentasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">352</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">3</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">untreated </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glecaprevir-Pibrentasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">233</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir-Daclatasvir</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">115</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glecaprevir-Pibrentasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">157</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Bourli&#x000e8;re M et al. </td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B104-viruses-17-00163" ref-type="bibr">104</xref>]</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1 <break/>(Polaris-1)</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">previously treated with a regimen containing an NS5A inhibitor </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir&#x02013;Velpatasvir&#x02013;Voxilaprevir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">263</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Placebo </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">152</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">1,2,3 (Polaris-4)</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">previously treated without a regimen containing an NS5A inhibitor </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir&#x02013;Velpatasvir&#x02013;Voxilaprevir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">182</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir&#x02013;Velpatasvir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">151</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td></tr></tbody></table></table-wrap></floats-group></article>